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Asymptomatic infection by enteric pathogens has been attributed to causing several outbreaks in the 
world. Common pathogens in this category are Vibrio cholerae, Salmonella typhi and Entamoeba 
histolytica infection of pregnant and lactating mothers. Exposure of the infant and the immune 
response during the early developmental years requires investigation. In the era of high HIV burden 
and the introduction of HIV prevention of mother to child transmission (PMTCT), many infants are 
exposed to these pathogens yet remain uninfected, however still face the challenge of high morbidity 
and mortality as compared to their unexposed and uninfected counterparts. The cause of such an 
anomaly has not been fully investigated. 
Aim  
The aim of this study is to investigate the burden and the immunological effect of asymptomatic 
enteric pathogen carriage in pregnant mothers, both HIV-infected and HIV-uninfected, and their 
infants in a high HIV burdened population of Harare, Zimbabwe.  
Methodology 
The study was a purposive cross-sectional sub-study in a birth cohort established at the University 
of Zimbabwe, College Of Health Sciences (UZ-CHS Birth Cohort). Participants were from the high-
density suburbs of Glenview, Kuwadzana and Dzivarasekwa. These suburbs were previously 
affected by the 2008 cholera epidemic as well as the 2012 typhoid outbreak that hit Harare, 
Zimbabwe. HIV rapid testing was performed at enrolment for mothers unaware of their HIV status 
or those who wanted HIV re-testing for various personal reasons. Those HIV infected with 
documented HIV status were asked to provide the evidence and were not re-tested.  
 xv 
 
The HIV status of neonates was ascertained using nucleic acid-based testing at the National Early 
Infant Diagnostic (EID) department based at the National Microbiology Reference Laboratory in 
Harare, Zimbabwe. The test made use of the Dried Blood Spot (DBS) samples collected from the 
infants at various time points.  
A total of 417 pregnant mothers were recruited based on their consent to provide stool samples, 
blood and urine for both the mother at recruitment and the infant upon delivery. A questionnaire to 
collect information on socio-demographic, clinical, delivery, water and sanitation, diarrheal history 
including antibiotic use, concurrent TB infections, ART regimen, planned baby feeding method, 
diet as well as nutritional data on probiotic uptake was administered to the mothers.  Of the 417 
mothers, only 204 mothers and 308 infants provided stool samples, which were cultured for enteric 
pathogens targeting Salmonella entrica serovar Typhi (S. typhi) and Vibrio cholerae, although in 
the process any non-lactose fermenter identified was considered a potential pathogen hence were  
further identified using an Analytical Profile Index (API; Biomerieux: France) and included in the 
study. The stool samples were also used for antigen ELISA targeting Entamoeba histolytica (E. 
histolytica) infection.  
The microbial results were used to calculate the prevalence of S. typhi, V. cholerae and E. histolytica 
in the study population. Data was analysed using STATA 13 analytical software. For further analysis 
on immunological factors in mother-infant pairs (MIPs), only paired mothers were included based 
on stool as well as plasma availability and the outcome of culture and ELISA results. Multiplex 
immunoassay utilised a 27-plex (IL-1β, IL-1r, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12p70, IL-13, IL-15, IL-17a, Eotaxin, basic PDGF, G-CSF, GM-CSF, IFN-, IP-10, MCP-
1(MCAF), MIP-1α, MIP-1β , PDGF-BB, RANTES, TNF- α and VEGF) cytokine profile and a 6-
plex isotyping (immunoglobulin: IgG1, IgG2, IgG3, IgG4, IgM and IgA) assay. Immunological 
assays were performed on the 39 MIPs purposively selected based on the culture outcomes as 
described, using BioRad Luminex machine according to manufacturer’s instructions.  
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 Based on the cytokine and immunoglobulin concentrations, maternal characteristics influencing 
infant cytokine and immunoglobulin production were analysed. 
Results  
The presence of V. cholerae nor S. typhi was detected but E. histolytica prevalence in mothers was 
calculated at 5.4% while in infants it was 5.6%. There was no significant difference in the prevalence 
of E. histolytica between HIV-infected and HIV-uninfected mothers (p=0.318) as well as between 
HIV-exposed uninfected and HIV-unexposed uninfected infants (p=0.056). E. histolytica infection 
was only noted in 1  HIV-uninfected mother-neonate pair.  The resistance to 3rd generation 
cephalosporines in the non-lactose fermenting bacterial isolates was detected.  
The cytokine groups of IL-1r, IL-4, IL-9, IL-12p70, IL-17a, G-CSF and PDGF-BB were 
significantly raised in E. histolytica infected compared to non-infected lactating mothers (p<0.05). 
In babies, E. histolytica carriage had no significant effect on the cytokine and immunoglobulin 
concentration.  In this study maternal E. histolytica carriage was significantly (p=0.026) correlated 
with infant Interleukin-12p70 (IL-12p70; p<0.026), Fibroblast Growth Factor-basic (FGF-basic; 
p<0.026), Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF; p<0.026) and Tumor 
Necrosis Factor (TNF; p<0.026)-α. The odds ratio of passing high levels of these cytokines to infants 
is reduced by 86% if the mother is a carrier of E. histolytica during pregnancy (OR: 0.14). Carriage 
of any form of enteric infection such as Non-lactose fermenters (NLFs) including E. histolytica 
significantly increased the levels of IL-1r, IL-4, IL-9, IL-10, IL-12p70, IL17a, G-CSF, GM-CSF, 
IFN-, PDGF-BB and TNF-α cytokines (p<0.05). 
 
However,  no significant difference in immunoglobulin levels was noted amongst the mothers. IL-
13 and G-CSF levels were significantly raised in HIV-infected compared to HIV-uninfected 
lactating mothers (p=0.0389 and p=0.0324, respectively).  
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IgA immunoglobulin levels were significantly raised among HIV-exposed uninfected than HIV-
unexposed uninfected infants. It has also been observed that maternal E. histolytica carriers are 
significantly more likely to have infants with low levels of IL-12p70, FGF-basic, GM-CSF and 
TNF-α cytokines and high levels of IgA immunoglobulin. HIV-infected mothers are significantly 
more likely to have infants with low levels of IgG2 and IgA immunoglobulins.  
 
Mothers giving birth at a mean age above 30.38 ±STD 6.09 years are more likely to have infants 
with low IgG4 levels (p=0.050).  Maternal HIV infection influences infant IgG2 and IgA 
immunoglobulin levels. Also, a maternal age of >30years reduces the odds ratio of passing high 
IgG4 to the infant (p=0.050). Maternal HIV infection influences infant IgG2 and IgA 
immunoglobulin levels. Infants born to HIV positive mothers are significantly associated (p=0.049) 
with lower odds of having high IgG2 levels, ie., reduced by 76% in infants born to HIV-infected 
mothers compared to those born to HIV-uninfected mothers. Similarly, an infant born to a HIV-
infected mother is significantly associated (p=0.035) with lower odds of having high IgA 
immunoglobulin levels compared to those born to HIV-uninfected mothers (OR: 0.22). 
Underweight/small to gestational age (SGA) babies (birth weight <2500g) were found to have 
significantly raised IL-7 cytokine levels compared to normal for gestational age (NGA) babies 
whose birth weight was >2500g  (p=0.0149).  
 
Conclusion 
 Asymptomatic enteric E. histolytica carriage is a reality in pregnant women and their neonates with 
the possibility of congenital transmission. We confirm that there is no V. cholerae carriage in 
Glenview, Dzivarasekwa and Kuwadzana, areas affected in the 2008 cholera epidemic in 
Zimbabwe. Moreover, there was no evidence of S. typhi carriage in these suburbs following the 
devastating 2012 typhoid outbreak. This study reports an expansive pro-inflammatory cytokine and 
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chemokine profile that is up-regulated in lactating mothers with asymptomatic enteric pathogens. 
HIV exposure had no effect on baby cytokine profiles. The importance of IL-7 in neonates requires 
further investigation as it might assist in reducing the prevalence of small for gestational age (SGA) 
babies. 
 
Significance and impact of study  
Our study culminates in the need to consider maternal characteristics such as age, HIV status and 
enteric pathogen carriage in pregnancy as these might impact on the infants’ immune responses. 
This will assist in the decisions on disease treatment and management of pregnant women and 
infants. The study findings also assist in developing effective immunotherapy in E. histolytica and 
HIV exposures and infections in an effort to promote maternal and child health.  
 
Keywords 
Cytokines, Immunoglobulins, HIV-infected mothers, enteric infections, E. histolytica, HIV-exposed 
infants, mother-infant pairs. 
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Chapter 1 : BACKGROUND AND LITERATURE REVIEW 
1.0 INTRODUCTION 
Low and middle-income countries battle with diseases afflicting the poor that include enteric diseases. 
Such diseases include, amongst others, typhoid, dysentery and enteric fever. These diseases can be 
endemic to particular geographical areas. These enteric diseases have become a cause of concern for 
researchers. Also, the challenges posed by diseases as malaria, HIV/AIDS and tuberculosis has 
resulted in many health practitioners, government officials and funders diverting most of their 
attention to these three main areas with a reduced focus on cholera, typhoid and dysentery. Lack of a 
holistic approach in the fight against enteric diseases in this era of high HIV burden may result in a 
huge burden of opportunistic infections. At present and during the past years diarrhoeal diseases 
predominate in Africa, specifically in Zimbabwe, viz., the cholera outbreak of 2008, that affected 
11735 cases and 484 deaths (4% death rate) was reported between August-December 2008, by the 
World Health Organization. Moreover, 50% of the cases came from a high-density suburb in 
Harare[1]. Although the cholera was widespread within Zimbabwe[2], the suburbs that were most 
affected were Dzivarasekwa and  Kuwadzana. These same suburbs were also the most affected by 
the typhoid outbreaks in 2008 and 2012[3].  In this regard, there is a likelihood that the surviving cases 
are still carriers of the deadly Vibrio cholerae with the ability to unknowingly spread the pathogen. 
The World Health Organization (WHO) has indicated access to safe drinking water, improved 
sanitation, exclusive breastfeeding for the first six months of life, good personal and food hygiene 
and health education about how infections are spread as effective measures to prevent diarrhoea[4]. In 
this study, we focus on the enteric diseases in particular typhoid, cholera and dysentery affecting sub-
Saharan Africa, specifically Zimbabwe. We also focus on the cytokine and antibody levels in HIV-





1.1 Background on Immunology and Epidemiology of Enteric infections 
 
The diseases considered in this study are caused by the Human immunodeficiency virus (HIV), 
bacteria (S. typhi and V. cholerae), and a protozoan (E. histolytica) thus microbiologists, 
immunologists, clinicians and epidemiologists have all exhibited extensive interest. Diarrhoea has 
been found to be the second commonest cause of deaths among the under 5-year-olds [5]. Subclinical 
pathogen carriage and enteropathy, without diarrhoea, are common, especially in developing 
countries. These intestinal pathogens “…drive a cycle of gut damage, malabsorption, chronic 
inflammation and failed mucosal regeneration, leading to malnutrition and susceptibility to further 
enteric infections”[5]. The gut microbiota has been noted to impact on an individual’s health status 
and play an important role in protective and susceptibility to infections.  
  
1.1.1 Gut Microbiota and its role in enteric infections 
Gut microbiota refers to the total microbes such as bacteria, viruses and fungi that live in a complex 
community[6,7] within the host gut and adapt to live with the host in a symbiotic nature. 
A. Development and composition of the gut microbiota 
Gut microbiota is critical in maintaining health in utero through postpartum to adulthood.  The 
composition and diversity have been noted to be influenced by age and diet[8] among other factors.  
Infant bacterial gut colonisation starts at the time the foetus is in the lower uterus although 
establishment takes off during birth[6,9]. Since the development of the gut mucosal barrier starts 
prenatally, pre-term babies are faced with challenges of gastrointestinal (GI) abnormalities resulting 
in higher morbidities and mortalities compared to their full-term counterparts[9]. During the last weeks 
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of gestation, the developing fetus sips some of the amniotic fluid[9] in preparation for the gut mucosa 
role for digestion and absorption of nutrients after birth.  
The type of the microbiota that invades the infant's gut depends on the mode of delivery, breastfeeding 
versus formula feeding and timing of introduction of solid foods at weaning stage[9]. Infancy is a 
critical stage in gut microbiota development and need not be disturbed, or else immune-related 
disorders will occur later in life. The type of the microbiota that invades the human gut early in life 
has a life-long effect hence it is crucial that parents introduce appropriate foods and conducive 
environment for the development of a healthy microbiota. Pre- and pro-biotic foods are very 
important in the human diet as these influence the nature of the gut microbiome[10]. It has been shown 
for example that the gut microbiome composition influences temperament at an early age[11]. This 
emphasises the need for a rich nutrition from early stages of child development such as breast milk 
and a balanced diet.  
 
Normal vaginal delivered infants tend to have gut microbiota resembling maternal vaginal microbiota 
which is mainly populated by Lactobacilli, Provitella or Sneathia. On the other hand, caesarian 
section delivered babies have gut microbiota resembling the maternal skin microbiota which is mainly 
Staphylococcus, Corynebacteria and Propionibacteria [9]. Breast milk influences the infant immune 
development such as the ‘…IgA and IgG, antimicrobial compounds such as lysozyme and lactoferrin, 
immune regulatory cytokines such as TGF-β and interleukin 10 (IL-10), and lymphocytes that express 
gut homing markers’. These breast milk factors influence the type of bacteria that will colonise the 
gastro-intestinal tract (GIT).  
 
Soon after birth, the infant gut normally has a higher demand for digestion and nutrient absorption in 
order to have a good maintenance of the rapid growth rate associated with the growing infants. This 
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demand is assisted by gut microbiota such as Bifidobacteria that digest human milk oligosaccharides 
(HMO).  
Infant gut microbiota is dynamic and develops rapidly then stabilises around 2-3 years when it 
resembles the adult gut microbiota[12]. However, at 5 years the infant gut microbiota is often not fully 
established[8]. 
B. Adult gut microbiota 
The Human Microbiome Project (2012) outlined the human gut microbiota[13]. The GIT is the highest 
colonised with 70% of all the human body microbes being located there.  In a healthy adult, about 
90% of this 70 % of the microbes originate from two major phyla which are the Firmicutes and 
Bacteroidetes and other phyla like Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria 
and Cyanobacteria are in smaller amounts[14]. The human gut microbiota is composed of bacteria, 
archaea, viruses, and eukaryotic microbes that reside in and on our bodies most of which cannot be 
explored through our routine cultures[15]. These microbes have tremendous potential to impact our 
physiology, both in health and in disease.  
 
C. The gut microbiota and human immunity to infections 
Microbiota contributes to metabolic functions, protect against pathogens, educate the immune system 
and through these basic functions directly or indirectly affect most of our physiologic functions[16]. 
Literature has revealed a stability in the composition of the gut microflora over time (microbiota 
equilibrium), which however can be affected by various confounders such as diet, diseases, host 
genotype etc [17].  
 
Diet influences the composition and diversity of the gut microbiota, in that people consuming a 
‘Western diet’ which is mainly protein, have more of Firmicutes and Proteobacteria as well as some 
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Bacteroides whilst people that consume an agrarian diet have increased amounts of Actinobacteria, 
mostly Prevotella[17; 18].  
High fibre diets favour the commensal bacteria, providing colonisation resistance to pathogenic 
bacteria usually associated with diseases such as colorectal cancer and IBD[18].  
 
The gut microbiota is in a position to assist the host in fighting infection through activities like 
production of antimicrobials such as bacterocins that are directed against members of the same or 
similar bacterial species[19], a process also known as colonisation resistance[20]. Gut microbiota also 
assists the host in the maturation of the host immune system and also competes for resources with the 
pathogens[16; 21]. A successful pathogen has to overcome the mucosal barrier. In some cases, naturally 
low-complexity of gut microbiota[19], and usage of antibiotics will destroy the normal gut flora and 
give rise to overgrowth of an opportunistic member of the intestinal microbial community[16] which 
then becomes pathogenic.  
 
Normally, microbiota offers a state of resilience to the effect of enteric pathogens and other factors 
that can trigger an imbalance which is referred to as dysbiosis.  Dysbiosis can either result in loss of 
beneficial organisms, loss of overall microbial diversity or excessive growth of potentially harmful 
organisms, which in most cases occur at the same time[18]. Microbial resilience is heavily dependent 
on the microbial diversity hence an increase in microbial diversity helps in maintaining microbial 
stability[17] which is important in controlling gut invasion by pathogenic organisms.  
 
Host inflammatory responses, despite being able to clear invading pathogens, can create an enabling 
environment. For example, virulence factors produced by virulent bacteria induce host inflammation 
against resident microbiota while favouring the growth of the virulent bacteria[19], hence interfering 
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with colonisation resistance and leading to host infections[16]. Overt or indigenous pathobionts may 
also take advantage of the dysbiosis[19].  
 
A variety of immune cells are found in the intestinal environment, harboured within Peyer’s Patches 
(PP) as well as in the Small Intestine Lymphoid Tissue (SILT) and the Intestinal Mesenteric Lymph 
Nodes (IMLN)[16]. The intestinal epithelial cells such as enterocytes and colonocytes express pattern 
recognition receptors (PRR) namely both extracellular Toll-like receptors (TLR) and intracellular 
NOD-like receptors (NLR). These receptors are insensitive to the normal flora but are activated by 
an infection, injury or any other assault. They respond by initiating the host inflammatory response[16; 
22; 23].  
 
The beneficial effects of TLR assist in pathogen recognition and bacterial clearance by leukocytes[22] 
with consequential detrimental damage to the host. An example is the activation of TLR4 in 
enterocytes which inhibits enterocyte migration whilst propagating and stimulating enterocyte 
apoptosis-factors which promote intestinal injury and at the same time preventing intestinal repair[22]. 
Successful pathogens modify their transcriptional actions to counter host immune responses including 
immunoglobulins (Ig) such as secretory IgA (s-IgA) which binds and agglutinates the pathogen[24]. 
Resident microbiota can also produce by-products that facilitate the growth of pathogenic organisms 
such as bile salt which promote Clostridium difficile spore germination[19].  
 
Intestinal dysbiosis has been linked with autoimmune and/or auto-inflammatory conditions such as 
Inflammatory Bowel Disease (IBD), metabolic disorders such as obesity, type 2 diabetes, allergies 
and neurological disorders[14]. Recently, faecal implant, also known as faecal microbial therapy has 
been recommended in some developed countries for the treatment of Clostridium deficile infections 
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(CDI) which resist antimicrobial drugs[18; 25–27]. Dysbiosis can result in inflammatory diseases of the 
gut as well as other distant organs and can sometimes have life-threatening effects[20].  
 
Another challenge is from bacterial translocation and sometimes bacterial products or their fragments 
into the bloodstream that may occur as a result of mucosal insult leading to a leaky gut. The microbial 
products or fragments that will enter into circulation from the lumen through the disrupted luminal 
T-junctions include endotoxins, bacterial DNA, peptidoglycan and lipopeptides. These products of 
microbial translocation usually trigger inflammation and disease in distal organs such as liver 
cirrhosis, acute pancreatitis, chronic kidney disease and chronic heart failure[28]. Markers of microbial 
translocation can be used for disease diagnosis such as IBD[29].  
 
Great progress in characterizing the structure of the microbiome recently has paved the way for ongoing 
and future studies on the functional interactions among the microbiota, pathogens and the host. The 
function of the microbiota is critical to understanding the role of the microbiota in human homeostasis 
and disease pathogenesis[30].  
 
1.1.2 Human Immuno-deficiency Virus (HIV)   
The HIV virus is one of the most studied virus to-date and has the primary target attack on the cells 
of the immune system causing their damage and exposing the host to opportunistic infection. 
Regardless of the infection route, the primary site of HIV-1 infection establishment had been reported 
to be the gut-associated lymphoid tissue (GALT) of the intestine where the HIV results in a 
“….significant mucosal CD4+ T lymphocyte depletion, induces an inflammatory state that 
propagates viral dissemination, facilitates microbial translocation and fosters establishment of one of 
the largest HIV reservoirs”[31]. It is from the gut that this virus damages the gut mucosal lining and 
get into the nearby cells and into the circulatory system and the lymph nodes. Due to the mucosal 
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damage, it is possible that HIV facilitates other systemic infections.  Significant efforts have been 
made in treating HIV/AIDS through lowering HIV multiplication and infection rate by the use of 
anti-retroviral drugs (ARVs). However, a vaccine is not available as yet.  
 
The ARVs have proven to be very effective in reducing viral load and improving the well-being of 
an HIV infected patient thereby reducing the rate of progression to AIDS development. These drugs 
have also been proven to prevent mother to child transmission of the virus hence the observed 
increased pool of HIV-exposed uninfected (HEU) neonates. Despite the lack of virus, the neonates 
have high morbidity and mortality rate compared to their HIV-unexposed uninfected counterparts. 
The study was designed to investigate the effect of HIV infection exposure and the resultant immune 
responses in HIV exposed but uninfected individual.  
 
1.1.3 Salmonella  
Salmonellae are Gram-negative intracellular bacteria that are facultative and belong to the species 
Salmonella enterica. Salmonella typhi and S. paratyphi are host-adapted to humans and can cause 
enteric fever. However, a small percentage of silent, chronic carriage of the Salmonella bacterium, 
usually in the biliary tract, can persist for decades, with the sustained dissemination of the disease[32]. 
 
This chronic carriage has been estimated at 1-3% of acute infections[33].  The fact that S. typhi and S. 
paratyphi are human-adapted pathogens, the chronic asymptomatic carriers will act as vehicles in 
transmitting the pathogens, especially in the previously uninfected communities hence posing a 
danger to the communities.  Enteric diseases as a result of S. typhi and paratyphi infection are a major 
public health problem in many developing countries[32]. It has also been noted by Roy and Malo, 
(2002), that the use of antimicrobials result in the loss of normal host flora hence favouring the 
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proliferation of Salmonella spp and also that the use of acid suppressor drugs which result in the loss 
of the acid barrier creates an increased susceptibility of the host to enteric pathogens[32].  
 
 
Salmonellosis is a serious disease in sub-Saharan Africa and is associated with HIV infection, malaria 
and poor nutritional status [34]. Despite Salmonella entering the host via the enteric system, initially 
infecting PP and mesenteric lymph nodes (MLN), it normally ends up infecting systemic organs[34] 
hence the need to understand the association of this pathogen with the gut microbiota. The initial 
immune response involves the recruitment of neutrophils around the infected PP and MLN where 
they are associated with IFN- production, together with the involvement of Natural Killer (NK) cells. 
The IFN- contributes to initial defence as well as in preventing bacterial dissemination[34]. 
Inflammatory monocytes also populate the infected PP and MLN and produce anti-bacterial factors 
like IL-1β, TNF-α and iNO. On the other hand, in the event that the Salmonella evades the host 
immune system, it ‘…exploits TLR/NLR signalling and cell death to establish infection’[35] and 
‘persists in M2 macrophages during chronic infection’[35], as well as benefitting from ‘…host-derived 
ROS, RNS, and antimicrobial proteins’ to successfully out-compete resident microbiota[35]. 
 
1.1.4 Vibrio cholerae  
Vibrio cholerae is also a bacterium that causes enteric infections. This Gram-negative, curved rod, 
flagellated bacterium can cause death to the infected individual within a couple of hours due to 
excessive loss of water if not attended to urgently. Symptoms of cholera have been observed to start 
from as early as a few hours to about 5 days after infection with symptoms ranging from mild to 
severe. Normally 1 in 20 (5%) of infected persons show severe symptoms of infection, however, 95% 
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may be asymptomatic but still continue spreading the bacteria for 7 to 14 days[36]. Severe cases 
experience diarrhoea and vomiting which cause dehydration with possible death. 
 
 
There is a paucity of current information on the host immune response to V. cholerae, hence further 
research in this area is warranted. The Cholera bacterium is non-invasive, and host protection from 
the bacterium is believed to be mainly conferred by secretory sIgA[37]. Children and adults respond 
similarly to cholera infection[38] but neonates still need their gut microbiota to develop as they have 
an immature gut and takes up to 2-3 years[12] or up to 5 years[8] for the gut microbiota to mature into 
that of an adult. The carrier state can persist for months and chronic biliary infections may persist for 
years with the intermittent shedding of the microbe. Sero-groups O1 and O139 are currently 
implicated in pathogenesis.  It is not possible for an individual to develop immunity for both serotypes 
after recovering from an infection resulting from only one of the two cholera serotypes[38].   
 
1.1.5 Entamoeba histolytica  
One interesting possibility that might drive the interaction in the direction of acute HIV/AIDS disease 
is when the individual is already infected with an intestinal parasite, leaving the mucosal defences 
damaged and perhaps less effective in eliminating the infectious organisms. A common parasite in 
Africa is Entamoeba histolytica; which is a single cell, pathogenic, enteric protozoan parasite that 
causes amoebic dysentery in humans. It also causes other invasive diseases such as genito-urinary 
amoebiasis, liver abscess, cerebral amoebiasis and respiratory tract infections. About 90% of human 
infections can be asymptomatic or the symptoms may be mild; this is, therefore, the most common 




Since E. histolytica damages the intestinal mucosa, there is a possibility that the presence of this 
pathogen will support HIV disease progression.  Of the 10% that exhibit symptoms, 80-98% are 
intestinal and 2-20% are extra-intestinal[40].  The seroprevalence of E. histolytica can range between 
5-55%[40]. There is no correlation between antibodies against the E. histolytica antigen and resistance 
of the host to the infection or host protective immunity[41].   
 
It is possible that multiple infections of E. histolytica, V. cholerae and  Salmonella could trigger a 
unique immune response that may lead to complications. In a surveillance study, Harris et al., (2009), 
observed co-infection with V. cholerae and intestinal parasites in Kolkata, India, amongst children 
aged 2-10 years who presented with acute diarrheal illness[42]. They demonstrated a 30% prevalence 
of concomitant parasitic infection with V. cholerae infection. It is however still not known whether 
an intestinal parasitic co-infection modifies the clinical manifestation of V. cholerae infection in 
humans[42]. On the other hand, Ayala-Sumuano et. al., (2013), noted the mixed infection of 
enteropathogenic bacteria and E. histolytica implicating an important role in the establishment of 
invasive disease via increasing adhesion, chemotaxis and cell damage capacity of trophozoites[43]. 
The fact that all these pathogens will eventually become systemic, highlights the possibility of 
congenital transmission. 
 
Infection by most enteric organisms will trigger an immune response by the host that persists for 
years after E. histolytica infection, whereas the presence of IgM antibodies is short-lived and can be 
detected during the present or current infection[39]. IgM is mainly indicative of fresh infections whilst 





Galactose-N-acetyl galactosamine (Gal-lectin) inhibitable lectin is the surface antigen of E. 
histolytica’s and one of its major adhesion molecules[45]. Wong-Baeza et al., (2009), identified the 
presence of lipo-peptido-phospho-glycan (LPPG) as one of the E. histolytica surface antigens. LPPG 
is slightly different from the lipopolysaccharide (LPS) found in Gram-negative bacteria and is one of 
the pathogens associated molecular patterns (PAMPs) found on parasite surfaces.   
The first encounter of the parasite is on the mucosal surface, the first line of defence, where pathogen 
recognition receptors (PRRs) such as TLRs are expressed by the host cells. Neutrophils are the first 
cells to express amoebicidal activity after activation by IFN- or TNF-α and LPS trigger the release 
of reactive oxygen species that kill the parasite. The intestinal epithelial cells (IEC) which provide 
the second line of defence, on their first encounter with the parasite, will recognise the Gal-lectin, or 
LPPG parasite surface antigens from the lysed trophozoites by means of TLR2 and TLR4/CD14 
resulting in activation of NF-κβ[40; 46; 47]. Once NF-κβ is activated, that triggers the release of pro-
inflammatory cytokines by monocytes releasing IL-8, IL-10, IL-12p40, and TNF-α. Cell-mediated 
IFN- or TNF-α production activates macrophages to destroy the parasite[40; 46].  
 
E. histolytica DNA also activates macrophages through interaction with TLR-9[46] thus destroying 
the parasite. In the process of evading the host immune response, the parasite decomposes the mucin 
barrier using their glycosidase enzymes and accesses the IEC. This process may also benefit the 
parasite as well as the gut microbiota in supplying of the carbon source of energy. Studies by Nakada-
Tsukui and Nozaki, (2016), have suggested that gut microbiota may influence the E. histolytica 
pathogenesis as germ-free animals were seen to be resistant to the parasite but ‘introduction of single 
bacterial species restored amebic pathogenesis’[47].  
 
E. histolytica is also in a position to degrade cytokines but this is not yet clear whether this act is 
beneficial or detrimental to the parasite. E. histolytica is also in a position to phagocytose or 
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togocytose the host cells including neutrophils, T lymphocytes and macrophages[47], putting itself in 
a position to survive the host immune defence mechanism, and able to chronically stay with the host. 
 
  
Generally, the host immune response to pathogenic effect involves the production of cytokines such 
as IFN-, interleukins (IL), tumour necrosis factor-alpha (TNF-α) and others. The pathogens will also 
develop survival strategies to evade the host immune system. Despite all the effort to conquer the 
pathogenic invasion, the host may fail to achieve its goal.  
 
There are several reasons including the presence of mutations on the cytokines themselves and 
weakened immunity due to other diseases such as HIV infection and cancer. The host natural defence 
failure can be assisted by the use of drugs may be successful depending on the susceptibility of the 
pathogen to the drugs. This susceptibility can also be due to a number of factors including mutations 
in the pathogen’s genome sequence. Because immune responses will also be affected by concomitant 
infections that are known to influence immune responses, the relationship between clinical disease or 
carrier development in people with HIV infection is also of interest.  
 
It is against this background, that the current prevalence of enteric pathogens in pregnancy and 
possible congenital transmission, as well as the type of immune response, that is more important in 
host carriers and continued exposure of the host to the pathogens, was carried out. Different factors 





                  Infection 
Host Factors; 
immunological, genetic or 
molecular factors that 
influence whether host is 
susceptible or resistant to 
infection.  
Environmental Factors 
(intestinal and geographical); 
e.g. acid suppression, use of 
antibiotics etc. results in host 
being more susceptible to 
infection 
Microbial Factors; genetic 
or molecular factors that 
influence virulence 
These factors affect host 
susceptibility loci 
 
Figure 1-1: Factors influencing host susceptibility to infection by microorganisms 
 15 
 
1.2 PROBLEM STATEMENT 
Zimbabwe has for several years been devastated by episodes of diarrheal infections that can be traced 
to Salmonella typhi, Vibrio cholerae and Entamoeba histolytica as the causative organisms. The 
Government of Zimbabwe together with various partners are making significant efforts to make sure 
safe water and good sanitation are provided to the citizens and that HIV prevention of mother-to-
child transmission (PMTCT) programmes coverage is increased. Unfortunately, the economic 
hardships being currently faced by the nation has made it difficult to provide a constant supply of 
treated water to the residents with a consequential high rate of water-borne infections. This has forced 
the residents to fetch alternative water supplies, most of which are unsafe for human consumption.   
As a result, waterborne disease episodes are rife and many deaths have occurred; for example the 
Zimbabwe 2008 cholera outbreak[1]. It is probable that a number of these surviving cases are still 
carriers of the cholera pathogen. 
 
History has shown that individuals pre-exposed to these pathogens have a high likelihood of 
becoming asymptomatic carriers. As a result, the diseases keep spreading to other individuals usually 
unknowingly in a snowball effect. Logically, it is far cheaper to treat one carrier individual compared 
to treating the multiple diseased individuals infected by one carrier since these diseased might end up 
being hospitalised, accumulating medical bills, and in worst case scenario, end up with loss of lives.  
 
In Zimbabwe, there is no or limited published data on the costing of diarrheal disease management. 
However, Zambia has given an indication of 3usd and 18usd general hospital costs for out-patient 
and in-patient respectively. Childhood diarrheal treatment cost in Zambia was estimated at 28usd and 
78usd for out-patient and in-patient respectively[48].  
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Similar trends can also be said for Zimbabwe as these are neighbouring countries.  There is, therefore, 
the need to identify the asymptomatic cases and treat to evade future outbreaks. Under normal 
circumstances, the human body has the ability to fight infections and can rectify the situation 
depending on the degree of infection. The immune status of an individual is also a confounder as far 
as the fight against infections is concerned. Infection by HIV results in an individual having a 
compromised immune system hence easily affected by opportunistic infections. This status is 
worsened during pregnancy. The pathogens can enter into the host bloodstream and there is a high 
possibility of them spreading to the unborn baby congenitally, hence the need for further 
investigation.  
 
In a case reported by Beyhan et al., (2016), it was observed that the baby that was delivered at 16 
weeks and died 15 minutes after delivery, had S. typhi in its tissues suggestive of vertical transmission 
of the pathogenic organism. This indicated the need to raise awareness that organisms not typically 
associated with TORCH (Toxoplasma gondii, other, Rubellavirus, Cytomegalovirus, Herpes Simplex 
virus) infection can nevertheless cause placental infection and pregnancy loss. S. typhi appears to be 
one of the “other” in the TORCH list[49]. 
 
The neonates born to the HIV-infected women who already have a compromised immunity will 
possibly have a poorly developed immune system hence the high morbidity and mortality rates. The 
fact that the mothers will be exposed to anti-retroviral therapy (ART) might expose the neonates to 
these drugs with the possibility of the neonates resulting in cytokine polymorphisms and this needs 
to be investigated. Mutations in the cytokine genes can also be a contributory factor on the possible 




Much of the information on these diseases is derived mainly from clinical cases, of infected people 
who consulted a health service facility. However, there is also the phenomenon of local people being 
carriers of the pathogens, in some cases, having multiple infections with no or minimal clinical signs. 
These carriers will keep on infecting new victims, usually unknowingly. For good disease control, 
there is need therefore to identify such carriers as well as the clinical cases and investigate the factors 
that influence whether an individual will become ill or not and whether they will eliminate the 
infectious organism or become a carrier and continue to transmit the infection.  
 
 HIV-exposed uninfected (HEU) neonates have been found to have a high morbidity and mortality 
rate. The main cause of this has not yet been established. There is, therefore, a need to investigate the 
possible causes of this anomaly or challenge. Currently, little has been done in trying to link enteric 
pathogens carrier state in pregnancy to the immune responses of neonates in an effort to investigate 
the challenge faced by HEU. Prendergast (2016)[5] has indicated an increase in HEU infants in the 
past decade, and has shown that, ‘Interest in the health outcomes of HIV-exposed, uninfected infants 
has grown in the past decade, with several studies suggesting that these infants have increased 
mortality rates, increased infectious morbidity, and impaired growth compared with HIV-unexposed 
infants’[50]. 
 
The information gathered through this study will help identify enteric pathogens carriers and decide 
on the best method to eliminate or control these waterborne infections in communities through 
possibly screening for the carriers and targeting them for treatment.  The information from this study 




The study will also assists policy-makers on decision making such as shift to immunotherapy in an 
effort to reduce the risk of antimicrobial resistance which has become a world-wide challenge as a 
result of the use of antimicrobials for treatment of diseases emanating from microbial infections.  
 
This study was carried out in a cohort of HIV-infected and HIV negative pregnant women and their 
neonates in 3 high-density suburbs of Kuwadzana, Glenview and Dzivaresekwa in Harare, 
Zimbabwe, which experienced high diarrheal infection episodes in the past. 
1.3 RESEARCH QUESTION  
What are the maternal and infant immunological responses to carrier status of enteric pathogens 
(Vibrio cholerae, Salmonella typhi, Entamoeba histolytica and other) in an HIV burdened 
community?  
1.4 AIMS AND OBJECTIVES: 
1.4.1 Aim: To investigate the maternal and infant cytokine and immunoglobulin response to carrier 
state of enteric pathogens (Vibrio cholerae, Salmonella typhi bacteria and Entamoeba 
histolytica protozoan) during HIV infection and exposure in a mother-child cohort in 
Zimbabwe.  
1.4.2 Main Objective-To investigate the maternal and infant cytokine and immunoglobulin levels in 
response to carrier state of enteric pathogens (Vibrio cholerae, Salmonella typhi bacteria and 
Entamoeba histolytica protozoan) during HIV infection and exposure in a mother-child cohort 
in Zimbabwe. 
1.4.3 Specific Objectives- 
a. To determine the baseline prevalence of the carrier state of enteric pathogens (Vibrio 
cholerae, Salmonella typhi bacteria and Entamoeba histolytica protozoan) in HIV-
infected pregnant women and their neonates. 
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b. To determine the cytokine name your profile and immunoglobulin name your profile 
profiles in the presence of single or multiple enteric infections (Vibrio cholerae, 
Salmonella typhi and Entamoeba histolytica) in HIV-infected pregnant women and their 
neonates. 




Chapter 2 : METHODOLOGY 
2.1 ETHICAL REVIEW AND ETHICS  
This study protocol was approved by Biomedical Research Ethics Committee (BREC – UKZN), 
approval code 409/15, Joint Research Ethics Committee (JREC), approval code 81/15, as well as the 
Medical Research Council of Zimbabwe (MRCZ), MRCZ/A/2043 and sample shipment was 
approved by the Research Council of Zimbabwe. During the course of the study, all study participants 
consented to take part in the study through responding to the questionnaire and providing samples. 
Confidentiality was observed through the use of anonymous numbers on samples which were 
generated by the lab and stripped of any participant identifiers. In the event that any participant sample 
was found to have pathogenic organisms, the main project PI was notified in order to link the 
participants to routine care. 
  
2.2 MATERIALS  
 
2.2.1. Selection of Participants and sampling 
Any HIV positive pregnant woman who could consent was invited to participate in the main study and 
enrolled if eligible. Those with obstetric complications, psychiatric and other conditions were excluded. 
For every HIV positive pregnant mother, the 10th HIV negative mother was recruited, taking cognisance 
of the HIV prevalence of about 12% in this population. Inclusion and exclusion criteria were used to 
select 417 pregnant women and their neonates who stay in high-density suburbs of Harare 
(Dzivarasekwa, Kuwadzana and Glenview) in Zimbabwe, and their neonates, both male and female in 
line with UZ-CHS recruitment and sample collection program, taking only samples collected once from 




2.2.2 Study Design 
The study was a purposive, cross-sectional study based on the availability of stool and plasma 
samples from the main Cohort study (UZ-CHS birth cohort). 
2.2.3 Sampled Sites 
The sampled sites were selected council maternity clinics in high-density suburbs of Harare 
(Kuwadzana, Glenview and Dzivaresekwa) in Zimbabwe where HIV-infected and uninfected 
pregnant mothers and their neonates were recruited. 
2.2.4 Inclusion criteria 
a. Pregnant woman 18 years of age and above at 28-36 weeks gestation based on the date of the last 
menstrual period (LMP). 
b. Pregnant woman 18 years of age and above at 28-36 weeks gestation with documented HIV status 
or willing to be tested. It is recommended to screen for HIV for all HIV negative pregnant women 
at every scheduled study visit through the main study.  
c. Pregnant woman 18 years of age and above at 28-36 weeks gestation planning to deliver at the 
study sites. 
d. Pregnant woman 18 years of age and above at 28-36 weeks gestation able to give informed 
consent. 
i. Willing to be followed together with her baby from delivery up to two years in the main study. 








2.2.5 Exclusion Criteria 
a. Pregnant women with severe obstetric complications and serious psychiatric disorders were 
excluded. 
b. Pregnant women who lived outside of the high-density suburbs of Harare (Kuwadzana, 
Glenview and Dzivaresekwa) in Zimbabwe. 
2.2.6 Biomedical samples collected 
Stool, amniotic fluid, urine and blood (including cord blood) samples were collected through the main 






2.3.1 Demographic and Clinical Data Collection 
Questionnaires were administered through the main study; UZ-CHS birth cohort. JREC reference 
number 81/15 and MRCZ reference number MRCZ/A/1968. The questionnaire was used to collect 
demographic and clinical information such as on water source, sanitation forms, any stomach 
discomforts, any exposures to antibiotic and antiacid treatment, history of enteric infection including 
TB infection, HIV status and drug regimen, delivery history, diet (fermented foods), alcohol uptake,  
etc from the selected population.  
 
2.3.2 Summary of the Study Process 
 
Out of 417 mothers who consented (218 (52.3% HIV-infected: 199(47.7%) HIV-uninfected) to take 
part in the main study, only 204 mothers (51% HIV-infected and 49% HIV uninfected) and 306 
infants (52% HEUs and 48% HUUs) were purposively included in this study based on availability of 
stool sample for culture and ELISA to screen for enteric pathogens. It is these mothers and their 
infants whose results were used to calculate the prevalence of enteric pathogens. Of those mothers 
and infants, only 111 mothers could be paired based on stool sample availability.  
 
Purposive sampling was also performed based on the culture results and HIV statuses of the 111 mother-
infant pairs for further analysis on immunological aspects on the pairs. Microscopy, culture and ELISA 
on the stool samples were conducted in Zimbabwe at the Biomedical Research and Training Institute 
(BRTI) Laboratories.  Sera from 39 out of 111 mother-infant pairs were taken for cytokine and antibody 
profiling at University of KwaZulu-Natal, Medical School, Optics and Imaging Centre, based on the 
microscopy, culture and ELISA results as explained earlier. Figure 2-1 illustrates the sampling process 






















Figure 2-1: Conceptual framework of the sample selection and analysis process used in the study 
Microbiome analysis and cytokine single nucleotide polymorphism (SNP) analysis were not performed due 
to limited funding and the complexity of the methodology that required outsourcing with a huge cost. 










417 pregnant  women  
(Recruited at enrolment and 
consented to sample collection) 
Only 204/417 pregnant mothers provided 
stool 
(51% HIV infected, 49% HIV uninfected) 
Only 306 infants provided stool 
(52% HEUs, 48% HUUs) 
111 mother-infant pairs from those who 
provided stool samples 
(51% HIV infected mothers and their HEUs; 
49% HIV uninfected and their HUUs) 
39 mother-infant pairs for immunology: 
Cytokine and antibody profiling 
[27 mother-infant pairs (either mother or infant 
with enteric infection), 12 mother-infant pairs 
with no enteric infection] 
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2.3.3 Laboratory Activities 
2.3.3.1 Stool, whole venous blood, cord blood and urine collection, transportation, 
processing and storage 
Stool, whole venous blood, cord blood and urine were collected, transported and processed using 
standard operating procedures. Briefly, the samples were transported in cooler boxes with ice packs 
as soon as possible from collection and processed on the same day of receipt.  
 
2.3.3.2 Detection of Carrier Individuals 
EZTyphi-Paratyphi DNA dipstick/ Typhidot-c kits developed by the University of Malaysia and 
traditional culture methods followed by Analytical Profile Index (API) were used for S. typhi. The 
use of EZTyphi-Paratyphi DNA dipstick/ Typhidot-c kits was an opportunity for validating the kits in 
the Zimbabwean setting. Responses from the questionnaire administered through the main study were 
also used to help with the identification of carriers. Culture was also employed for V. cholerae and S. 
typhi as well as ELISA for E. histolytica carrier identification. 
2.3.3.3 Cytokine detection methods 
Multiplex detection of 27 serum cytokines for mother-infant pairs (MIP) using Bio-plex Pro Assay 
27-plex kit, Bio-Rad, USA, which is a magnetic-bead based multiplex immunoassay, was employed 
following the manufacturer’s instructions and as summarised in Figure 2-2. The study measured 27 
cytokines namely IL-1β, IL-1r, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-
15, IL-17a, Eotaxin, basic PDGF, G-CSF, GM-CSF, IFN-, IP-10, MCP-1(MCAF), MIP-1α, MIP-















2.3.3.4 Immunoglobulin detection methods 
Multiplex detection of 6 serum immunoglobulins for mother-infant pairs (MIP) using 6-plex Pro 
Assay 6-plex kit, Bio-Rad, USA, which is a magnetic-bead based multiplex immunoassay, was 
employed following the manufacturer’s instructions and as shown in Figure 2-3. The study measured 
antibodies IgG (IgG1, IgG2, IgG3 and IgG4), IgA and IgM and relating findings to infection status. 
 
Figure 2-3: Bioplex Immunoglobulin Assay Workflow 
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Figure 2-4 summarises the study laboratory activities. Biomedical samples collected are indicated in 
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Chapter 3 : Determination of the baseline prevalence of the carrier state of enteric 
pathogens (Vibrio cholerae, Salmonella typhi bacteria and Entamoeba histolytica 
protozoan) in HIV-infected pregnant women and their neonates. 
 
Despite all the challenges on diarrheal outbreaks faced by Zimbabwe, there is still a paucity of 
information with regards to prevalence of such pathogens as Vibrio cholerae, Salmonella typhi 
bacteria and Entamoeba histolytica protozoan in the general population. This is even worse in 
pregnant women. This chapter aims to determine the baseline prevalence of carrier state of enteric 
pathogens (Vibrio cholerae, Salmonella typhi bacteria and Entamoeba histolytica protozoan) in HIV-
infected pregnant women and their neonates and is presented in a manuscript format which has been 
submitted to the African Journal of Reproductive Health (AJRH) and is under review (proof of 
submission is attached as appendix 8A7).  The serum samples from identified carrier individuals were 
then subjected to cytokine and immunoglobulin profiling to determine influence carrier state on the 
cytokine and immunoglobulin production in the mother-infant pairs as described in Chapter 4. The 
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Despite the success of Prevention of Mother to Child Transmission (PMTCT) in Zimbabwe, higher 
morbidity and mortality rates in HIV-exposed and uninfected (HEUs) compared to the unexposed 
infants (HUUs) remains a challenge, the cause is still unknown and requires investigation. 
Objectives:  
This study aimed at determining the burden of asymptomatic enteric pathogens in particular Vibrio 
cholerae, Salmonella enterica serovar Typhi and Entamoeba histolytica in pregnant women and their 
infants; and possible congenital transmission.  
Methods  
Maternal faecal and urine, as well as infant faecal samples, were cultured for Vibrio cholerae and 
Salmonella enterica serovar Typhi detection. Antigen ELISA was used for E. histolytica detection. 
Non-lactose fermenting bacterial isolates were identified using analytical profile index using E.coli 
ATCC 25922 control organism and antimicrobial susceptibility done thereafter.  
Results 
Neither V. cholerae nor S. typhi was detected. An E. histolytica prevalence of 5.4% in the mothers 
and 5.6% in infants was observed. There was no significant difference in prevalence of E. histolytica 
between HIV-infected and HIV-uninfected mothers (p=0.318), being borderline between for HIV-
exposed uninfected and HIV-unexposed uninfected infants (p=0.056).  Resistance to 3rd generation 
cephalosporines was detected in the non-lactose fermenting bacterial isolates. One HIV-uninfected 





Asymptomatic carriers of E. histolytica exist in pregnant mothers with possible risk of congenital 
transmission. Our study highlights the need to screen and treat pregnant women to control congenital 
transmission of enteric pathogens in an effort to contribute to the regulatory strategies for the high 
morbidity and mortality rate in HEUs.  
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Worldwide consideration and available resources are focused mainly on diseases such as malaria, 
HIV infection and TB whilst enteric diarrheal diseases such as cholera, typhoid and dysentery get 
little resources. A holistic approach is required to fight enteric diseases, especially in HIV burdened; 
resource-limited countries, to avert opportunistic infections. Diarrhoea has always plagued Africa. In 
Zimbabwe, a cholera outbreak in 2008 claimed lives (4% death rate)[1; 2] and spread across 10 
Provinces of Zimbabwe even affecting the neighbouring country of South Africa. In 2012,  a typhoid 
outbreak predominantly affecting the density suburbs of Kuwadzana and Dzivarasekawa[3]. Also, 
since the onset of the 2016-2017 rainy season, Zimbabwe has experienced a typhoid outbreak with 
1380 cases and two deaths reported[4]. According to the WHO guidelines on control of diarrheal 
disease, preventive measures as good hygiene practices and provision of safe water require urgent 
consideration[5]. Opportunistic infections are frequent in immunocompromised patients. It is perhaps 
plausible that when infected with an intestinal parasite, the individual develops an acute disease that 
lowers the mucosal defence hence is less effective in eliminating the infection. A common parasite 
in sub-Saharan regions and in Zimbabwe is Entamoeba histolytica. This parasite can also cause 
invasive diseases such as genito-urinary amoebiasis, liver abscess, cerebral amoebiasis and 
respiratory tract infections[6; 7]. Since this protozoan damages the intestinal mucosa, it is plausible that 
it promotes HIV/AIDS disease progression.    
 
The typhoid fever bacterium, Salmonella enterica serovar Typhi, whose sole natural host and 
reservoir are humans[3] is a major public health concern [8]. The biology of this pathogen that makes 
it affect humans as the definitive host is not well understood[9] hence there is a need for more research. 
Apart from the faecal/urine-oral transmission route of typhoid [9], vertical transmission in-utero [10] is 




An irresponsible use of antibiotics causes the loss of the normal host flora with the resultant 
proliferation of Salmonella spp. It is highly possible that the abuse of acid suppressor drugs may 
predispose the loss of the acid barrier thereby increasing the susceptibility of the host to enteric 
pathogens. Host response to enteric pathogen infection varies from mild- to severe- to death. In the 
first group, the patient may receive treatment and heal completely clearing up all the infecting 
pathogens; however in the second group,  the patient may heal after treatment but without clearing 
up all the pathogens in their systems and thirdly the patient may acquire the infection and not display 
any signs and symptoms such as a self-limiting diarrhoea. The latter two groups were considered 
asymptomatic carriers that can spread the disease or spark outbreaks of diarrhoeal disease.  
 
Asymptomatic carriers of Typhoid are estimated at 1-3%[11]; V cholerae (95%)[12] and E. histolytica 
(90%) [6] In a report from Canada, 75% asymptomatic V. cholerae prevalence was noted[13]. Notably, 
there is a paucity of information on asymptomatic carriers of these pathogens in the general 
population in Zimbabwe.  Such burden of disease remains poorly described in the Zimbabwean 
general population and in pregnancy yet such diseases may play an important role in the morbidity 
and mortality rates observed in the HIV-exposed uninfected (HEU) neonates.   
 
The objective of this study was to determine the baseline prevalence of the carrier state of enteric 
pathogens carriers, in particular, V. cholerae, E. histolytica and S. enterica ser. Typhi in a cohort of 





MATERIALS AND METHODS 
Ethics approval and consent to participate 
The study protocol was approved by the Medical Research Council of Zimbabwe (Approval Code 
MRCZ/A/2043) and the Biomedical Research Ethics Committee of University of KwaZulu-Natal, 
Durban, South Africa (Approval Code BE409/15). Informed consent forms were approved by the 
Medical Research Council of Zimbabwe.  All study participants consented to take part in the study 
such as responding to the questionnaire and providing samples. 
 
Study population and sampling 
This was a sub-study based on samples collected from a cohort of HIV-infected (HIV+) and HIV-
uninfected (HIV-) pregnant women. These women resided in high-density suburbs of Harare, 
Zimbabwe, namely Dzivarasekwa, Glenview and Kuwadzana during the period February 2016 to 
February 2017. Only women 18 years of age and above at 28-36 weeks gestation based on last 
menstrual period (LMP), having documented HIV status or willing to be tested for HIV and who were 
able to give an informed consent were recruited into the study. 
 
Study procedure 
Pregnant women visiting the local clinic were invited to participate in the study, upon which they 
would sign an informed consent if they agree to take part in the study, including details of their infant 
upon delivery. A questionnaire was then administered to capture such baseline data as, demography, 




Biomedical Samples Collected 
Stool and urine were collected from mothers at recruitment or close to delivery for culturing of V. 
cholerae and S. typhi. The stool was also used for E. histolytica microscopy and ELISA. The first 
voided stool or stool as close to delivery as possible was collected from infants for V. cholerae and 
S. typhi culture in addition to E. histolytica diagnosis using microscopy and ELISA. When it was 
difficult to collect stool, an anal swab was collected. 
 
Vibrio cholerae detection in mothers and infants 
A rice grain size fresh stool samples were cultured in alkaline peptone water overnight at 37±2 oC to 
enhance the growth of V. cholerae before culturing on Thiosulphate Citrate Bile Salt (TCBS) solid 
media, which is also a selective media for V. cholerae. Yellow colonies from TCBS were considered 
presumptive and a gram test, oxidase test as well as string tests were further performed on the 
presumptive colonies.  
 
The presumptive yellow colony isolate were gram stained to check for gram-positive curved rods 
which are indicative of V. cholerae. Oxidase test with oxidase strips was also performed using a 
wooden or plastic applicator to check for colonies that turn positive (deep purple) within 10 sec of 
testing. A string test was further done by mixing the fresh colonies with 0.5% aqueous solution of 
sodium deoxycholate on a clean microscope slide. Any positive samples were confirmed with 






 Salmonella typhi detection in mothers and infants 
A rice grain size fresh stool sample was cultured in 20ml selenite F broth for 24hr at 37±2 oC to 
enhance the growth of Salmonella bacteria before culturing on Xylose Lysine Deoxycholate (XLD) 
and MacConkey agars which are also selective media for Salmonella. For infants, if a swab was 
available, one anal swab was cultured as described for the mother stool samples. Pink colonies from 
XLD and pale colonies on MacConkey were considered presumptive and gram tested. Any 
presumptive colonies were aimed for confirmation with Analytical Profile Index 20E (API; 
Biomerieux: France).  
 
EZTyphi-Paratyphi DNA Dipstick kit for detection of Salmonella typhi in mothers and infants 
Qualitative detection of S. enterica ser. Typhi and S. enterica ser. paratyphi A from mother and infant 
stool samples were performed using EZTyphi-Paratyphi DNA Dipstick kit, (Universiti Sains Malaysia, 
Health Campus, Malaysia) following the manufacturer’s instructions. The same stool sample from 
selenite broth culture was used for solid media culture and also used for DNA extraction required for 
PCR in the EZTyphi-Paratyphi DNA Dipstick procedure. The amplicons were subjected to a lateral 
flow assay to determine the presence or absence of Salmonella species, S. typhi or S. paratyphi A.  
 
Microscopy and Antigen ELISA detection of E. histolytica in mothers and infants stool samples 
A wet mount technique was used, where approximately 2mg of stool sample was mixed with a drop 
of 0.85% sterile normal saline on a clean glass slide. Examination for trophozoites and cysts for E. 
histolytica was performed at X10 and X40 initial magnification. A qualitative detection of E. 
histolytica antigen in stool samples was performed on all samples following microscopy. ELISA 
detection was performed using the r-biopharm Ridascreen (C1701) AG kit (Darmstadt, Germany).  
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Approximately 0.1g of stool sample or an anal swab was diluted in 1ml of sample diluent buffer 
(diluted 1:11). A swab is estimated at 0.1g stool sample. One hundred microliters (100µl) of each 
sample, as well as positive and negative controls, were used in the analysis following the 
manufacturer’s instructions. Optical Density (OD) was read at 450/620nm wavelength using the 
URIT-660 ELISA reader.  
 
Other organisms isolated from culture 
All non-lactose fermenters (NLFs) from culture were treated as potential pathogens and were 
subjected to API testing for identification, using an isolate suspension equivalent to a 0.5 McFarland 
standard according to the manufacturer’s kit insert. After API testing, the isolates were then subjected 
to antibiotic susceptibility testing (AST) using the following drugs; penicillin, gentamycin, 
ampicillin, clindamycin, vancomycin, trimethoprim, ampicillin, cotrimoxazole, ertapenam and 
ceftriaxone. Organisms resistant to cefpodoxime  (3rd generation cephalosporin), were considered 
suspect for Extended Spectrum Beta-Lactamase (ESBL) carriage and were subjected to ESBL and 
inducible AmpC enzyme testing using the six antibiotics which were cefpodoxime (CPD10), 
cefpodoxime/clavulanate (CPDCV), Cefepime (CPM30), Cefepime clavulanate (CPMCV), 







A total of 417 participants were enrolled in the study and 52.7% (218) were HIV-infected. Of the 
HIV-infected participants, 91.3% (199) were on ART. The majority of the participants who were on 
ART, 96.2% (194), received TENOLAM E, whilst only 2.7% (5) received TENOLAM N.  Nearly 
half of the participants (48.5%) were aged between 26 and 35 years with a mean age of 29 years (SD 
±6.3).  The participants’ area of residence was almost equally distributed among the three high-
density suburbs of Harare.  The majority (96.5%) of the participants reported the use of a flush toilet 
located inside or outside the house. A majority (62.8%) of participants reported the use of borehole 
untreated water in 85.4% of the households (Table 3-1a).   
 
Only 4.1% of the households reported always having sewage overspill in the immediate proximity of 
their home with 17.3% also reporting that a household member had suffered from the diarrheal disease 
in the last month (Table 3-1b). The majority of the participants had normal stool (79.8%) according 
to the Bristol stool chart. Only 10.3% were currently on antibiotic treatment at the time of recruitment 
(Table 3-2a). The majority of the participants (93.0%) had live births, being predominantly males 
(51.3%).   
 
The mean neonate weight was 3060 grams (SD± 507) with the majority (82.3%) having a weight 
above 2500 grams.  Underweight births were significantly higher (17.5%) in HIV-infected compared 
to HIV-uninfected mothers (11%) (p=0.002; Table 3-1b). The presence of an inside flush toilet 
(p>0.042) compared to having an outside flash toilet was significantly associated with the presence 
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of enteric pathogens Table 3-2a. E. histolytica infection was significantly higher in mothers that 
indicated an absence of current diarrhoea (96.6%) compared to those with current diarrhoea (p= 
0.034), at the time of the study (Table 3-2b). 
 
Type of Samples Collected from Mother and the Infant 
A total of 204 mothers [HIV- (n=100; 49.0%) and HIV+ (n=104; 51.0%)] were included in this study 
based on the availability of stool samples. Only 111 (54%) mothers stratified as HIV-infected (n=54; 
48.6%) and HIV-uninfected (n=57; 51.4%), could be paired to their neonates based on the availability 
of stool whilst 93 mothers remained unpaired. A total of 78.5% (306) infants stratified as HEUs 
(n=159; 52.0%) and HUUs (n=147; 48.0%), had stool samples available hence were included in the 
study. No HIV-exposed infected (HEI), if present, had samples available at the time of collection.  
 
Stool Sample diagnosis for V. cholerae, S. typhi Detection and Other Pathogens 
Neither S. typhi nor V. cholerae were detected in the cultured samples from both mothers Table 3-3 
and infants Table 3-4. No Salmonella spp, S. typhi or S. paratyphi A was detected by this method. 
Although neither Salmonella enterica serovar Typhi nor Vibrio cholerae was detected, some non-
lactose fermenters were isolated. Using API on stool samples from mothers, a total of eight NLFs 
were isolated of which three were from the urine of HIV-infected mothers, two of which were 
identified as Hafnia alvei and Proteus mirabilis. One NLF could not be identified by API and was 
eliminated from further analysis.   
 
Five of the NLF organisms were from the stool of HIV-uninfected mothers and were identified as 
Enterobacter cloacae (two isolates), Acinetobacter baumannii, Rhanella aquatilis and Proteus 
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mirabilis. Two E. histolytica (1%) were identified from the 204 mother stool samples by microscopy. 
Also, one Giardia lamblia and one Schistosome NLF were identified in the process. A total of 10 
NLFs were isolated from infant stool samples of which five were from HEUs and identified as 2x 
Escherichia coli 1, 2x Morganella morganii and 1x Raoultella ornithinolytica. The other five of the 
10 NLF isolated were from HUUs and identified as 2x Escherichia coli 1, 1x Morganella morganii, 
1x Escherichia fergusonii and 1x Citrobacter freundii.   
 
Antibiotic Susceptibility  
Organisms from the mothers’ stool indicated that H. alvei had a similar antimicrobial profile to the 
P. mirabilis isolates. R. aquatilis, H. alvei (intermediate resistance) and the two E. cloacae were 
resistant to cefpodoxime, which is an indicator of possible ESBL carriage hence were subjected to 
ESBL and AmpC testing. R. aquatilis, E. cloacae and H. alvei isolates did not possess ESBL carriage. 
However, H. alvei from HIV-infected mother and E. cloacae from HIV-uninfected mother were 
found to possess derepressed AmpC enzyme. While infants samples showed four isolates from HUUs 
and four from HEUs conferred resistance to cefpodoxime hence were tested for possibility of ESBL 
carriage. These four isolates from HUUs were M. morganii, E. fergusonii, E. coli 1 and C. freundii 
and those from HEUs were E. coli 1, R. ornithinolytica, and 2x M. morganii.  
 
Generally all the isolates were resistant to the antibiotics tested but were mainly susceptible to 
ertapenam, gentamycin and ceftriaxone (results not shown). None of the infant isolates carried ESBL 
or derepressed AmpC enzymes. Two M. morganii isolates (one from HEU and the other from HUU) 
however possessed inducible AmpC enzyme as indicated by resistance to FOX and blunting between 




Antigen ELISA for the detection of E. histolytica 
Off the 204 maternal stool samples, 49% (100) HIV-uninfected and 51% (104) from HIV-infected, 
were tested and 11 mothers were E. histolytica infected. The prevalence of E. histolytica was 5.4% 
(95% CI; 2.7%-9.4%). The prevalence of E. histolytica among the HIV-infected was 3.9% (95% CI; 
1.6%-10.9%) and among the HIV-uninfected was 7.0% (95% CI; 2.9%-13.9%). Two of the 11 E. 
histolytica infected were detected by microscopy and were included for further immunological 
investigations under the current study.  
 
There was no significant difference in the E. histolytica prevalence between the HIV-infected and 
HIV-uninfected mothers (p=0.532) (Table 3-3).  Majority of mother E. histolytica cases had normal 
stool type and frequency, reporting no history of diarrhoea in the past month, and no incidence of 
sewage overspill for more than a year as shown in Table 3-2a. Only 78.5% (306) neonate specimens 
were collected at enrolment and tested. Of the 306 infants tested, 17 were positive for E. histolytica 
indicating a prevalence of 5.6% (95% CI; 3.2%-8.7%).  The prevalence of E. histolytica among HEUs 
group was 3.1% (95% CI; 1.0%-7.2%) and among HUUs group was 8.2% (95% CI; 4.3%-13.8%). 
The difference in E. histolytica prevalence between HEUs and HUUs was not significant (p=0.056) 
as shown in Table 3-4. 
 
A total of 111 mother-infant pairs (MIP) were obtained based on the availability of stool samples.  
Only one (1%) E. histolytica infected mother who was HIV-uninfected could be linked to her E. 




Ten mothers out of the 111 MIP (9%) were E. histolytica infected while their infant pairs were E. 
histolytica uninfected. Five infants out of the 111 MIP (5%) were E. histolytica infected while their 




DISCUSSION   
This study demonstrates that the prevalence of E. histolytica in pregnant mothers participating in the 
study population was 5.4%. However, the prevalence was not significantly different between HIV-
uninfected and HIV-infected groups. These findings are corroborated by other studies where 6.7% E 
histolytica was reported by Guo et al.[14] in pregnant women in the Caribbean region. In infants, the 
baseline prevalence in our study was 5.6% and similarly, there was no significant difference between 
HEU and HUU groups. Also, E. histolytica prevalence was 3.9% within the HIV-infected pregnant 
mothers group and 7.0% within the HIV-uninfected pregnant mother group. Interestingly, we did not 
see a higher prevalence of the parasite in HIV-infected individuals compared to the HIV uninfected.  
 
In most studies, E. histolytica prevalence in HIV-infected population has been shown to be higher 
than in the HIV-uninfected group[15; 16], which was not the case in our study. This could be attributed 
to the fact that all the HIV-infected pregnant women were urban dwellers who have access to 
reasonable sanitary conditions. ART uptake may have some anti-parasitic effects however this 
requires further investigation. In India, a prevalence of 3.7% was reported in HIV-infected individuals 
with diarrheal diseases[17]which is about 50% lower than what was found by Guo et al.,[14] and to our 
study. Certain ante-natal activities and hygiene lessons may have influenced the general health of the 
study population hence the low prevalence of E. histolytica.  
 
One interesting finding was the detection of E. histolytica in a week old neonate, indicating the 
possibility of a congenital transmission. It was, however, not possible to confirm this result in the 
mother since her stool sample could not be collected before delivery. Also, one mother-baby pair with 




Despite the possibility of congenital transmission, poor hygiene within the household may have 
contributed to this prevalence. This implicates the possibility of E. histolytica contamination of the 
household and its immediate surrounding, nonetheless, no follow-up was done to verify this 
assumption. Interestingly, the majority of E. histolytica cases were found in a population of mothers 
who use flush toilets. In the resource-poor setting of Zimbabwe, detergent usage required to clean the 
toilets is often minimal. Notably, the majority of mother E. histolytica cases had normal stool type 
and stool frequency.  This might be as a result of stabilisation of infection due to the chronic carriage 
of the organism where the protozoa and the host develop a mutual relationship.  
 
The E. histolytica infected samples by microscopy could not be confirmed by ELISA probably 
because of formalin that was added to the sample which confounded the antigen-antibody reaction. 
Moreover, the low prevalence rate (1%) for microscopy compared to ELISA (5.4%) suggests that 
microscopy alone may lead to false negative diagnosis hence compromise patient management. It 
also indicates that the technique requires highly experienced individuals to improve on the pick-up 
rate, sentiments recently shared by some researchers[16;  18; 19]. However, even with highly experienced 
scientists, the pick rate (sensitivity) of the microscopy methods to detect E. histolytica is very low, at 
<10%[6]. 
 
No S. enterica ser. Typhi bacteria were detected in contrast to similar studies that reported a 
prevalence between 1-3% [11; 20]. The relatively small sample size may have confounded the 
prevalence rates. Also, it is possible that exposure from previous pathogen outbreaks may contribute 




Our results are in concordance with Im et al.,[21] who reported 1077 and 1359 individuals from 
Guinea-Bissau and Senegal, respectively an absence of S. typhi after stool culture. Although in one 
study, S. enterica ser. Typhi bacteria was isolated in aborted foetus suggesting the possibility of the 
bacteria crossing the maternal-fetal interface[10], there is likelihood of protective immunity gained 
from the mothers that could have been passed onto the unborn babies.  Despite an absence of V. 
cholerae detection in our study, it has been indicated that long-term convalescent carriers of V. 
cholerae are rare[22] and this could possibly explain its absence in our study. The last cholera outbreak 
in Zimbabwe was in 2008, hence it is possible that the carriers have since cleared their systems; totally 
resulting in observed 0% V. cholerae detection rate.  
 
It is expected that the prevalence of pathogen carrier status in the HIV-infected pregnant mothers is 
high compared to their HIV-uninfected counterparts since it is a known fact that HIV-infected 
individuals have a compromised immune system. This is also expected in HEU infants compared to 
their HUU counterparts since we hypothesize that HIV-infected mothers have a compromised 
immunity and fail to stimulate an effective immune response of this kind to the newly born baby. The 
HIV-infected group were on ART, hence there is a possibility of ART playing a role in the 
individual’s defence against these pathogenic organisms. This, however, needs to be investigated 
further. Organisms such as R. ornithinolytica, E. cloacae, E. fergusonii, E. coli and M. morganii that 
were noted in our study form part of the normal flora. R. aquatilis is a very rare enteric, Gram-negative 
rod, whose natural habitat is water. These organisms confer resistance to pathogenic organisms 
especially their resistance to Cotrimoxazole, a drug used as prophylaxis in HIV-infected people, and 




The discovery of the inducible AmpC enzyme in two of the M. morganii isolates and derepressed 
AmpC in one E. cloacae and one P. mirabilis is an indicator of resistance to 3rd generation extended 
spectrum cephalosporins and cephamycins hence posing challenges to clinicians. Generally, some 
beta-lactams especially ceftriaxone have been seen to cause overproduction of AmpC enzymes 
through induction or derepression of inactive AmpC genes responsible for the production of the 
AmpC enzyme. This will cause some pathogens which initially appear sensitive to beta-lactams to 
suddenly become resistant[23–25]. It is really important to treat any AmpC producers as important as 
these may contribute to treatment failures observed in the health sector. The generalised resistance to 
antibiotics in the usually known gut commensals support earlier reports that gut microbiota act as a 
reservoir of antibiotic resistance[26–28], major concerns being of the possible transfer of this antibiotic 
resistance carriage to potential pathogens. There is also a possibility that these gut microflora carrying 
resistance genes becoming pathogenic possibly via mutations as the use of antibiotics are at an 
increase with some abuse being noticed where antibiotics are sometimes being prescribed for viral 
infections like common colds.  
 
In a study by Al-Hulu et al.,[29], R. ornithinolytica, was isolated first time in clinical samples and was 
resistant to a number of antibiotics including cefotaxime[29] which is a third generation cephalosporin.  
E. fergusonii, also isolated in the present study was resistance to cefpodoxime among other tested 
antibiotics, despite it being normally a gut commensal it has been indicated in several studies to cause 
diseases in humans as well as animals, making it a possible zoonotic pathogen. It has been isolated in 





P. mirabilis was also isolated in one of the mother urine samples. This organism is part of the gut 
normal flora hence could have managed to cross over to the urinary tract. Other studies have however 
indicated the organism in some clinical gastroenteritis cases. H. alvei has been seen to have ‘limited 
pathogenicity in humans that may cause clinically significant infections only in immunocompromised 
individuals’[31]. This could be the reason why in the current study it was isolated from a urine sample 
of an HIV-infected pregnant mother.   
 
Conclusion 
This study has established the prevalence of asymptomatic carriers of enteric pathogens in 
Zimbabwean pregnant women as 5.4% for E. histolytica and 0% for both V. cholerae and S. typhi. In 
infants, the prevalence is 5.6 % for E histolytica and 0% for both V. cholerae and S. typhi. 
Asymptomatic enteric carriers are a reality in the Zimbabwean pregnant women with a possibility of 
congenital transmission which might be a possible cause for the unexplained high morbidity and 
mortality rates in HIV-exposed and uninfected infants. There is need therefore to screen pregnant 
women for these pathogens to avoid transmission to the infants.  Asymptomatic infections demand 
the need to be on the alert to control potential outbreaks. The study has also shown that there is no V. 
cholerae carriage in the vulnerable Glenview, Kuwadzana and Dzivarasekwa, Zimbabwe areas post 








Study limitations and recommendations 
This was a cross-sectional sub-study and at least 3 fresh consecutive stool samples for cultures could 
not be obtained. There is, therefore, need to use antigen ELISA kits on stored stool samples, which 
could not be done in the current study due to limited funding. In addition, there is need to strengthen 
monitoring of urinary tract infections in pregnant women since some organisms had been isolated in 
urine from three of the 204 pregnant women.  
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Table 3-1: Baseline Demographic & Clinical Characteristic of Enrolled Study Patients on 
Education Level, Type of Water Source and Toilet of Enrolled Study Patients in Relation to 
HIV Status 
 
 All HIV Negative  HIV- infected p-value 
Characteristics   N= 417 % N= 199 % N= 218 % 
HIV Status Positive 218 52.3 - - 218 100 
 
Negative 199 47.7 199 100 - - 
Completed Primary 59 14.2 32 16.1 27 12.4 
Some Secondary 85 20.4 35 17.6 50 22.9 
Completed  Secondary 245 58.8 119 59.8 126 57.8 
Tertiary 20 4.8 10 5.0 10 4.6 
Age ( years) ≤25 141 33.8 88 44.2 53 24.3 
<0.001 
26-35 204 48.9 85 42.7 119 54.6 
≥36 66 15.8 25 12.6 41 18.8 
Missing 6 1.4 1 0.5 5 2.3 
Mean Age (STDEV) 28.8(6.3) 27.4(6.4) 30.1(5.9) <0.001 
Area of Residence Location 1 (Dzivarasekwa) 127 30.5 65 32.7 62 28.4 
0.564 
Location 2 (Glenview) 128 30.7 59 29.7 69 31.7 
Location 3 (Kuwadzana) 161 38.6 74 37.2 87 39.9 
Missing 1 0.2 1 0.5 0 0.0 
Type of Toilet used 
 
Flush Toilet (Inside) 225 54.0 106 53.3 119 54.6 
0.604 
Flush Toilet (Outside) 177 42.5 86 43.2 91 41.7 
Other (eg Blair) 11 2.6 4 2.0 7 3.2 
Missing 4 1.0 3 1.5 1 0.5 
Water Source 
 
Piped into dwelling 107 25.7 56 28.1 51 23.4 
0.089 
Public tap 11 2.6 2 1.0 9 4.1 
Borehole 262 62.8 118 59.3 144 66.1 
Protected Well 30 7.2 19 9.6 11 5.1 
Commercial Bottled  6 1.4 3 1.5 3 1.4 
Missing 1 0.2 1 0.5 0 0.0 
Treated Water 
    
 
No 356 85.4 169 84.9 187 85.8 
0.828 Yes 58 13.9 29 14.6 29 13.3 
Missing 3 0.7 1 0.5 2 0.9 
Sewage Overspill Never 278 66.7 126 63.3 152 69.7 0.583 
 
Always 17 4.1 9 4.5 8 3.7  
 
Monthly 56 13.4 30 15.1 26 11.9  
 
Annually 60 14.4 29 16.1 28 12.8  
 
Missing 6 1.4 3 1.0 4 1.8  
Diarrhea in the  
last month 
Never 334 80.1 157 78.9 177 81.2 
0.547 Yes 72 17.3 35 17.6 37 17.0 




Table 3-1b: Baseline Demographic and Characteristic of Enrolled Study Patients on Food Taken, 
Type of Stool, Gender, Birth Weight and others in Relation to HIV Status  
 
 All HIV Negative  HIV infected p-value 
Characteristics   N= 417 % N= 199 % N= 218 % 
Fermented foods taken Yoghurt (Yes) 248 59.5 122 62.3 126 18.3 0.466 
 
Cheese (Yes) 91 21.8 51 25.6 40 14.6 0.072 
 
Lacto(Yes) 342 82.0 166 83.4 176 80.7 0.476 
 
Mahewu(Yes) 355 85.1 178 89.4 177 81.2 0.018 
Type of Stool Separate hard lumps(constipated) 7 1.7 4 2.0 3 1.4 
0.670 
Lumpy/sausage like (slightly 
constipated) 
28 6.7 12 6.0 16 7.3 
Sausage shape with cracks (normal) 121 29.0 58 29.1 63 28.9 
Smooth soft sausage/snake (normal) 212 50.8 106 53.3 106 48.6 
Soft blobs with clear cut edges (lack 
of fibre) 
24 5.8 11 5.3 13 6.0 
Mushy consistency with ragged 
edges (inflammation) 
18 4.3 7 3.5 11 5.1 
Liquid consistency with no solid 
pieces (inflammation) 
2 0.5 0 0.0 2 0.9 
Missing 5 1.2 1 0.5 4 1.8 
Currently on  
Antibiotic 
Yes 43 10.3 3 1.5 40 18.4 
<0.001 No 372 89.2 196 98.5 176 80.7 
Missing 2 0.5 6 3.3 2 1.0 
Currently  have 
diarrhea 
Yes 14 3.4 9 4.5 5 2.3 
0.034 No 387 92.8 178 89.5 209 95.9 
Missing 16 3.8 12 6.0 2 1.0 
Live Births 
 




Still to deliver 26 6.3 15 7.4 11 5.0 




Missing 5 1.3 2 1.3 3 1.9  
 
0.550 
Male 159 51.3 79 52.7 80 50.0 
Female 146 47.1 69 46.0 77 48.1 
 
Neonate 
 Weight (grams) 
   
 




<2500 47 12.05 11 6.0 36 17.5 
≥2500 321 82.3 164 89.1 157 76.2 
Missing 22 5.6 9 4.9 13 6.3 






Table 3-2a: Baseline demographic & Clinical Characteristic of Enrolled Study Patients on education 
level, type of water source and toilet in Relation to E. histolytica Detection. 
Characteristics  All E. histolytica- infected  E. histolytica- uninfected p-value 
N= 204 % N= 11 % N= 193 % 
E. histolytica Positive 11 5.4 11 100 - - 
- 
Negative 193 94.6  - -  193 100 
Education Level Some Primary 0 0.0 0 0.0 5 100 
0.202 
Completed Primary 0 0.0 0 0.0 53 100 
Some Secondary 85 20.4 3 7.7 36 92.3 
Completed  Secondary 245 58.8 8 7.5 99 92.5 
Tertiary - - - - - - 
-Age ( years) ≤25 62 30.4 2 18.2 60 31.1 
0.405 
26-35 98 48.0 8 72.7 90 46.9 
≥36 41 20.1 1 9.1 40 20.7 
Missing 3 1.5 0 0.0 3 1.6 
Mean Age (STDEV) 29.3(6.5) 31.0(5.5) 29.2(6.5) 0.374 
Area of Residence Location 1 (Dzivarasekwa) 73 35.8 4 36.4 69 35.8 
0.920 Location 2 (Glenview) 66 32.4 3 27.3 63 32.6 
Location 3 (Kuwadzana) 65 31.9 4 36.4 61 31.6 
Type of Toilet used 
 
Flush Toilet (Inside) 108 52.9 6 54.6 102 52.9 
 
0.042 
Flush Toilet (Outside) 90 44.1 4 36.4 86 44.6 
Other (eg Blair) 4 2.0 0 0.0 4 2.1 
Missing 2 1.0 1 9.1 1 0.5 
Water Source 
 
Piped into dwelling 63 30.9 1 9.1 62 32.1 
0.454 
Public tap 7 3.4 1 9.1 6 3.1 
Borehole 119 58.3 8 72.7 111 57.5 
Protected Well 12 5.9 1 9.1 11 5.7  
Commercial Bottled  3 1.5 0 0 3 1.6 
Treated Water 
    
 
No 169 82.8 9 81.8 160 82.9 
0.896 Yes 32 15.7 2 18.2 30 15.5 
Missing 3 1.5 0 0.0 3 1.6 
Sewage Overspill Never 145 71.1 10 90.9 135 70.0 
0.601 
Always 10 4.9 0 0.0 10 5.2 
Monthly 23 11.3 1 9.1 22 11.4 
Annually 25 12.3 0 0.0 25 13.0 




Table 3-2b: Baseline demographic & Clinical Characteristic of Enrolled Study Patients on Type of 
Stool, Diarrhoea Episodes and Others in Relation to E. histolytica Detection.  
Characteristics  All E. histolytica 




N= 204 % N= 11 % N= 193 % 
Diarrhoea in  
the last month 
Never 177 86.8 10 90.9 167 86.5 
0.677 
Yes 27 13.2 1 9.1 26 13.5  
Type of Stool Separate hard lumps(constipated) 1 0.5 0 0.0 1 0.5 0.183 
Lumpy/sausage like (slightly constipated) 13 6.4 0 0.0 13 6.7  
Sausage shape with cracks (normal) 61 30.0 4 36.4 57 29.5  
Smooth soft sausage/snake (normal) 104 51.0 6 54.6 98 50.8  
Soft blobs with clear cut edges (lack of fibre) 11 5.4 0 0.0 11 5.7  
Mushy consistency with ragged edges 
(inflammation) 
8 3.9 0 0.0 8 4.2 
 
Liquid consistency with no solid pieces 
(inflammation) 
2 0.9 1 9.0 1 0.5 
 
Missing 4 1.9 0 0.0 4 2.1  
Stool Frequency More than Twice daily 77 37.7 5 45.5 72 37.3 0.886 
Once daily 110 53.9 6 54.6 104 53.9  
Once every two days 13 6.4 0 0.0 13 6.7  
More than once every two days 1 0.5 0 0.0 1 0.5  
Missing 3 1.5 0 0.0 3 1.6  
Currently on 
Antibiotic 
Yes 190 93.1 2 18.2 11 5.7 0.251 
No 13 6.4 9 81.8  181 93.8  
Missing 1 0.5 0 0.0 1 0.5  
Currently on  
Antacid 
Yes 1 0.5 0 0.0 1 0.5 0.944 
No 202 99.0 11 100.0 191 99.0  
Missing 1 0.5 0 0.0 1 0.5   
Currently  
having   
 diarrhoea 
Yes 3 1.5 1 9.1 2 97.4 
0.020 
No 197 96.6 9 81.8 188 1.0   




Table 3-3: Culture Results for the HIV infected and HIV Negative Mothers 
  ALL HIV Negative HIV infected                    p-value 
Type  n=204 % n=100 % n=104 %  
Isolates (Positive)         
S. typhi  0  0.0 0  0.0 0 0.0 - 
V. cholerae  0  0.0 0  0.0 0 0.0 - 
E. histolytica  11 5.4 7 7.0 4 3.9 0.318 
Other Pathogens         
E.cloacae  2 1.0 2 2.0 0 0.0 0.147 
G.lamblia (microscopy)  1 0.5 0  0.0 1 1.0 0.326 
Hafnia alvei  1 0.5 0  0.0 1 1.0 0.326 
P.mirabilis  2 1.0 1 1.0 1 1.0 0.978 
Rahnella Aquatilis  1 0.5 1 1.0 0 0.0 0.307 
Acinetobacter baumannii  1 0.5 0  0.0 1 1.0 0.326 




















Table 3-4: Culture Results for the HIV-Exposed-Uninfected (HEUs) and HIV-Unexposed-
Uninfected (HUUs) neonates 
 ALL HUUs HEUs p-value 
Type n=306 % n=147 % n=159 %  




0  0.0 0  0.0 0  0.0 - 
0  0.0 0  0.0 0  0.0 - 
17 5.6 12 8.2 5 3.1 0.056 
Other Pathogens        
Citrobacter freundii 
 
1 0.3 1 0.7 0 0.0 0.298 
Escherichia coli 
 
4 1.3 2 1.4 2 1.3 0.937 
Escherichia fergusonii  
 
1 0.3 1 0.7 0 0.0 0.298 
Morganella morganii  
 
3 1.0 1 0.7 2 1.3 0.608 







Chapter 4 : Determination of the effect of single or multiple enteric infections (Vibrio 
cholerae, Salmonella typhi and Entamoeba histolytica) on cytokine profiles of pregnant 
women and their neonates in an HIV prevalent setting. 
Chapter 3 focused on screening pregnant women and their infants for asymptomatic enteric pathogens 
carriage using methodologies described in Chapter 3. Individuals screened in Chapter 3 were 
purposively sampled based on enteric pathogen isolation and HIV status. The individuals that were 
infected with enteric pathogens were matched with their neonates. Also, the neonates were matched 
according to enteric and HIV infection. Below is a manuscript emanating from this study and is under 
review (Manuscript number JMII-D-18-00007 as shown in appendix 8A8) 
Immune response to Entamoeba histolytica asymptomatic infections in pregnant women and 
their infants in a high HIV prevalence setting. (Under Review in the Journal of Microbiology, 
Immunology and Infection-JMII) 
Agness Farai Nhidza1, Thajasvarie Naicker1, Babill Stray-Pedersen3, Tawanda Chisango1, Edson 
Sibanda1, Aziah Ismail6, Bernard Ngara4, Tsitsi Bandason2, Curtis Makaza2, Kerina Duri4, Takafira 
Mduluza1, 5. 
1Optics & Imaging Centre, School of Laboratory Medicine and Medical Sciences, College of Health 
Sciences, University of KwaZulu-Natal; KwaZulu-Natal South Africa 
2Biomedical Research and Training Institute, Harare, Zimbabwe 
3Letten Foundation, Harare, Zimbabwe 
4Immunology Department, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe 
5 Biochemistry Department, University of Zimbabwe, Harare, Zimbabwe 
6Institute of Research and Molecular Medicine (INFORMI), Universiti Sains Malaysia, Health 
Campus, George Town, Malaysia 





Asymptomatic Entamoeba histolytica carriage in pregnant women poses an underlying risk to 
congenital infection, transmission to the infant during breastfeeding and as a potential for outbreaks 
in areas of high HIV prevalence. This study aimed at investigating the immunological status of 
asymptomatic enteric pathogen carriers in mother-infant pairs and to determine factors associated 
with cytokine profiles amongst mother-infant pairs in a high HIV burdened community in Harare, 
Zimbabwe.  
Methodology: 
Serum samples from 39 mother-baby pairs were analysed for inflammatory cytokine and 
immunoglobulin profiles using BIOPLEX immunoassay technology. 
Results:  
IL-1r, IL-4, IL-9, IL-12p70, IL-17a, G-CSF and PDGF-BB levels were significantly raised in E. 
histolytica infected compared to non-infected lactating mothers (p<0.05). In babies, E. histolytica 
carriage had no significant impact on the cytokine and immunoglobulin concentrations. Carriage of 
any form of enteric infection such as Non-lactose fermenters (NLFs) in addition to E. histolytica 
significantly increased concentration levels of IL-1r, IL-4, IL-9, IL-10, IL-12p70, IL17a, G-CSF, 
GM-CSF, IFN-, PDGF-BB and TNF-α cytokines (p<0.05) but no significant differences in 
immunoglobulin levels among the mothers. IL-13 and G-CSF levels were significantly raised in HIV-
infected compared to HIV-uninfected lactating mothers (p=0.0389 and p=0.0324 respectively). IgA 
immunoglobulin levels were significantly raised among HIV-exposed uninfected than HIV-
unexposed uninfected infants (p=0.0282). IL-7 was significantly raised in low birth-weight babies 
(birth weight <2500g) compared to normal birth-weight babies (p=0.0149). 
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Conclusion: Pro-inflammatory cytokines and chemokines were highly raised in lactating mothers 
with asymptomatic enteric pathogens. HIV exposure had no effect on baby cytokine profiles. 
Importance of IL-7 low birth-weight babies needs further investigations 
 
Significance and impact of study  
Our study highlights the need to check cytokine profiles in pregnant women and their infants to assist 
in decision making linked to treatment and prevention in times of pandemics and to assist in 
developing effective immunotherapy for reducing the observed high morbidity and mortality rates in 
HIV-exposed uninfected infants.  
 
Keywords 






Asymptomatic chronic intestinal carriage of parasites is very common worldwide and can confer an 
advantage to the host by shifting immune responses from Th1 to Th2 against bacterial infections, 
such as Helicobacter pylori, hence avoiding host tissue damages[1]. Entamoeba histolytica commonly 
colonises the human gut asymptomatically[2]. Immunity plays a very critical role in an individual’s 
protection against infection and diseases. Several immune cells and proteins are involved in body 
defence mechanism in a rather complex phenomenon. Cytokines and antibodies (immunoglobulins) 
are some of the proteins involved in the body defence system. Immunoglobulin G (IgG) is the only 
antibody capable of crossing the placenta and has four sub-classes (IgG1, IgG2, IgG3 and IgG4) each 
of which can represent different immune mechanism for fighting infection. IgG1 has the strongest 
and longest half-life compared to all IgG subclasses and has strong complement binding activity[2–4].   
IgG1 and IgG3 target microbial proteins, IgG2 targets microbial proteins and IgG4 ‘weakly responds 
to many antigens and possesses a blocking activity to IgG1- and IgE-mediated immune functions’[2]. 
In contrast to IgG2,  IgG4, IgG1 and IgG3 drive inflammatory processes and antigen clearance via 
their affinity to C1q and binding to FcyRI, FcyRII and FcyRIII that are expressed on neutrophils, 
natural killer cells and tissue macrophages[2–4].   
 
The body has to maintain a balance between fighting against pathogenic organisms and its own 
immune cells[5]. Maternal antibodies cater for the infant for the first three to twelve after delivery 
months in which case IgG will be in the infant circulatory system since it manages to get into the 
placenta and IgA will occur mainly in the infant gut through breast milk[6]. It is impossible to produce 





As such, it is logical that the fetus or newborn benefits both from maternal immunity as well as herd 
immunity, which simply stated, refers to the ability to reduce the probability of wide-spreading of an 
infection from an infected individual to susceptible, uninfected individuals in a population. It is hence 
important that women get immune to life-threatening infectious agents first before pregnancy to be 
able to transfer protective immunity to the baby which of course depends on the maternal accumulated 
immunological experience as well as herd immunity[6]. It is therefore important to vaccinate mothers 
in preparation for pregnancies.  
 
Cytokine is the general term for small protein molecules that signal between cells and they are named 
in line with their source, for example, interleukins are produced by leukocytes, monokines are 
produced by myeloid cells and lymphokines are produced by lymphocytes.  It is however not unusual 
for a cytokine to be produced by two different cell types, for example, IFN-ᵞ which is produced by T 
cells as well as NK cells[3]. Cytokines can also have different effects on different cell types, for 
example, IFN- can result in activation of macrophages in an effort to destroy intracellular microbes. 
On the other hand, this same cytokine can activate B cells for antibody class switching. Interferons 
are produced by quite a variety of cells in response to viral infections[3]. In asymptomatic chronic 
carriage of E. histolytica, the cytokine Interleukin-10 (IL-10) was observed to be lower and IL-4 
raised compared to amoebic liver abscess patients[2].  
 
In pregnancy, the foetus is recognised as a foreign body[7], as a result, there is need to strike a balance 
between the mother’s immune response and that of the growing baby to avoid rejection of the 
pregnancy. The immune system of the pregnant mother should, therefore, be robust enough to be able 
maintain the most important period in species conservation. This contradicts earlier thinking that a 
woman’s immunity is weakest during pregnancy[6].  
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In pregnancy, both maternal and fetal immune systems should be strengthened in order to protect the 
two from environmental damage. It is, therefore, appropriate to refer to pregnancy as a unique 
immune condition that is modulated, but not suppressed. This unique behaviour explains why 
pregnant women respond differently to the presence of microorganisms or its products[8]. Successful 
pregnancies have been linked to T-helper 2 (Th 2) immune responses while deleterious ones to T-
helper 1 (Th 1) immune responses[7; 9].  
 
During pregnancy of immune-stimulated mothers, maternal blood and amniotic fluid cytokines IL-1, 
IL-6, IL-12, TNF-α and G-CSF increase transiently and appear to influence fetal immune 
development, a phenomenon known as fetal programming[10].  Mandal et al.,[11] has also noted a rapid 
development and increased responsiveness of Th1, Th17 and cytotoxic effector T-cell subsets by 
infants born to immune-stimulated mothers. Immune insult occurring during pregnancy has been 
linked to negative effects on the developing fetus such as increased risks of autism[12]. Increased levels 
of inflammatory mediators such as Macrophage Chemotactic Protein (MCP-1/CCL2), C-reactive 
proteins (CRP), matrix metalloproteinase (MMP)-9, Interleukins (IL)-4, IL-5 and Interferon (IFN-γ) 
have been linked to neurodevelopmental disorders like autism[12].  Previous studies have associated 
male fetal sex with up-regulated maternal pro-inflammatory cytokines particularly G-CSF, IL-12p70, 
IL-21, and IL-33 as well as angiogenic factors in particular PlGF and VEGF while female fetal sex 
was linked to an upregulation of regulatory cytokines particularly  IL-5, IL-9, IL-17, and IL-25 
although IL-27 increase throughout pregnancy is not affected by fetal sex. Maternal analyte 




Cytokines are the major constituents of the placental microenvironment[14].  It is important to note 
that a cytokine can have dual purpose for example, IL-6 can act as both pro-inflammatory as well as 
regulatory. Besides involvement in inflammation and infection/ disease responses, IL-6 is implicated 
in metabolic, regenerative and neural process regeneration[15]. IL-6, IL-1 and TNFα cytokines are 
mostly elevated in inflammation hence have been targeted for therapeutic intervention[15].  
  
IL-13 is an immunoregulatory cytokine that up-regulates CD23, MHC class II expression as well as 
promotion of the immunoglobulin E (IgE) isotype switching of B cells. Macrophage activity is also 
downregulated resulting in the inhibition of pro-inflammatory cytokines and chemokines. IL-13 takes 
part also in B-cell maturation and differentiation[16]. This cytokine hence can act as pro- as well as 
anti-inflammatory. IL-13 clusters with IL-3, IL-4, IL-5 as well as CSF2 (GM-CSF) on chromosome 
5q but however positioned closer to IL-4. Granulocyte-Colony Stimulating Factor (G-CSF) also 
known as Colony Stimulating Factor 3 (CSF3), is a cytokine as well as a hematopoietic growth factor 
produced by macrophages, endothelium as well as other various immune cells[17; 18].  G-CSF has been 
found to stimulate production and proliferation of white blood cells. In fact, they stimulate the 
proliferation and differentiation of neutrophil progenitors in the bone marrow, to maintain the number 
of mature and functional neutrophils[17–19] and stimulate the release of mature granulocytes into the 
blood-stream[17]. In previous studies, G-CSF has been suggested as a reliable marker for use in 
neonates suffering from early- or late-onset of neonatal sepsis[17].  
 
Pregnancy-associated upregulation of IL-13, IL-4 and IL-10 has been observed in previous studies 
and these might result in promotion of the production of IgG4 instead of IgG1 and IgG3 leading to a 




As a result of the plausible efforts by health experts to reduce HIV burden world-wide through mother 
to child prevention programs such as PMTCT, HIV-exposed uninfected children (HEUs) have greatly 
increased in numbers. However, the major challenge facing this group of children is the high 
morbidity and mortality rates compared to their HIV-unexposed counterparts (HUUs). Currently, the 
greatest concern of most researchers in the field of HIV and AIDS and paediatricians is to investigate 
the cause of such anomalies between HEUs and HUUs.  
 
In this study, we hypothesise that asymptomatic chronic enteric infections influence the mother 
cytokine and immunoglobulin profiles as well as those of the infants. We investigated the relationship 
between mother cytokine profile and that of her neonate in relation to enteric exposure and HIV status. 
In one study by Abdulla et al.,[21] chronic amoebic infections caused prolonged inflammation resulting 
in auto-immune diseases.  
 
Some studies have found higher levels of IL-1ra, IL-6, IL-8, IP-10 and MIP-1a in infants with proven 
infections although an overlap to those without proven infections was also noted[22] which could point 
towards intensive studies in this subject. Current studies have indicated a high morbidity and mortality 
rates in HIV-exposed uninfected neonates (HEUs) compared to their HIV-unexposed uninfected 
(HUUs) counterparts. The actual cause of this observation is yet to be established.  
 
This study hypothesises the asymptomatic carriage of enteric pathogens by pregnant mothers and the 
influence of these pathogens on the maternal immune response in particular cytokines and antibodies, 
to have a bearing on the neonate cytokine and antibody production in both HEUs and HUUs.   
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The objective of this study was to investigate the effect of enteric pathogens carriages on the cytokine 
(IL-1β, IL-1r, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17a, Eotaxin, 
basic PDGF, G-CSF, GM-CSF, IFN-, IP-10, MCP-1(MCAF), MIP-1α, MIP-1β , PDGF-BB, 





MATERIALS AND METHODS 
Ethics approval and consent to participate 
The study protocol approval was granted by the Medical Research Council of Zimbabwe, Approval 
Code MRCZ/A/2043 and Biomedical Research Ethics Committee (BREC) of University of 
KwaZulu-Natal, Durban, South Africa, Approval Code 409/15.  All study participants consented to 
take part in the study.  
Study population and sampling 
This study was a sub-study based on stored plasma samples collected from a cohort of HIV-infected 
(HIV+) and HIV-uninfected (HIV-) pregnant women during the period February 2016 to February 
2017. The study participants were from Dzivarasekwa, Glenview and Kuwadzana, three selected 
high-density suburbs in Harare, Zimbabwe, based on previous burden of pathogens of interest. Those 
recruited in the study were women of at least 18 years of age, within 28-36 weeks gestation in relation 
to last menstrual period (LMP), with known and documented HIV status or if unknown or not 
documented, should be willing to be tested for HIV and were able to give an informed consent. 
 
Study procedure 
The pregnant women on their routine antenatal care visits were invited to participate in the study. 
After agreeing, an informed consent was administered and signed by participant and the interviewer 
before a questionnaire administration to capture demographic data such as HIV status, ART uptake 
and regimen. The mothers were followed up to delivery where information on delivery mode, infant 




Those mother-baby pairs (MBP) who were able to provide stool samples had cultures and ELISA 
done on the samples. The MBPs that had E. histolytica, as well as other enteric pathogens detected, 
were considered for cytokine and antibody profiling. 
 
Sample collection 
Venous blood was collected on recruitment and processed for plasma and stored. Only sera for 
mothers and infants with Entamoeba histolytica infections and other microbial infections was used in 
this study based on the preliminary antigen E. histolytica ELISA and culture results. Sera from 
mothers without E. histolytica or other microbial infections were also used as controls. This was done 
for both HIV-infected and HIV-uninfected mothers and their infants. Infant stored sera as close to 
delivery as possible was used in the study and selection of the sera was based on the mother enteric 
infection status as well as the infant enteric statuses for both HIV-uninfected (HUU) and HIV-
exposed uninfected (HEUs) neonates. All the infant samples were collected at recruitment and 
majority of infant samples were collected at 14 weeks and 6 weeks as indicated in Table 4-1. Those 
that seroconverted were also included despite absence of enteric pathogens (Table 4-2). 
 Table 4-1: Infant serum sample collection points 
Serum point of collection Frequency Percentage 
10 days 4 10.26 
30 days 1 2.56 
6 weeks 15 38.46 
10 weeks 4 10.26 
14 weeks 15 38.46 








Table 4-2: Serum sample collection point for sero-convertors and mother Viral Loads at 
recruitment 
Infant ID Sample collection point Time seroconverted Mother viral load at recruitment 
Infant 1 14 weeks 6 months 43 280 copiesml-1 
Infant 2 14 weeks 10 weeks <20 copiesml-1 
 
Cytokine and chemokine profiling 
Bio-plex Pro Assay 27-plex kit, (Bio-Rad, USA), a magnetic-bead based multiplex immunoassay, 
was used to perform Cytokine profiling of 27 serum cytokines (IL-1β, IL-1r, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17a, Eotaxin, basic PDGF, G-CSF, GM-CSF, 
IFN-, IP-10, MCP-1(MCAF), MIP-1α, MIP-1β , PDGF-BB, RANTES, TNF- α and VEGF) for 
mother-baby pairs (MBP) following the manufacturer’s instructions. The plate washings were 
performed on a Bio-Plex Pro and Bio_Plex Pro 11, wash station and incubation was performed at 
room temperature on a Bio-Rad Shaker Fax – 2200.  
Data acquisition was performed using Bio-Plex® 200 system (Bio-Rad, California, USA) which uses 
Bioplex Manager Software. The data output was given as Median Florescence Intensity and 
concentration in pgml-1. The software extrapolated concentrations that were outside limit of 
quantification (LOQ), which is the minimum level the machine could detect. Those that were below 
limit of detection (LOD-which is the minimum level the machine could quantify), or were not present 
at all, were given as out of range low (<OOR). Values above upper limit of quantification (ULOQ-





6-plex Antibody Profiling 
Bio-plex Pro Assay immunoglobulin isotyping 6-plex kit, Bio-Rad, USA, was used to perform 
antibody profiling of 6 antibodies (IgG1, IgG2, IgG3, IgG4, IgM and IgA) for mother-baby pairs 
(MBP) as per protocol above.  
 
Data Analysis 
 Non-parametric methods were employed to analyse both cytokine and immunoglobulin data. The 








A total of 39 MBP were considered for cytokine and immunoglobulin profiling.  Of the 39 mothers, 
15 (38.5%) were HIV-infected and 24 (61.5%) were HIV negative. Nine (23.1%) of the 39 mothers 
had E. histolytica infection, of which 7 (17.9%) were HIV-uninfected and 2 (5.1%) were HIV-
infected. Of the 39 babies, 12 (30.8%) were HIV-exposed uninfected (HEUs), 3 (7.7%) were sero-
convertors and 24 (61.5%) were HIV-unexposed uninfected. Out of the 39 babies, 8 (20.5%) had E. 
histolytica infection of which 5 were HUUs and 3 were HEUs. Two of the five infected HUUs had 
coinfection, one with E. fergusonii and the other with E. coli 1 (E. fergusonii and E. coli). The three 
babies who sero-converted had no identified enteric pathogens.  
 
Sampling and and biomedical samples collected 
Purposive sampling was done based on the presence of an enteric infection and HIV status. Samples 
with no enteric pathogens were also included as controls. A total of 39 MIP sera were analysed for 
cytokine and immunoglobulin profiles.  
 
Cytokine and Immunoglobulin Profiling using Multiplex Assay 
Cytokine and antibody levels in mothers during pregnancy compared to their babies after delivery  
Cytokines and chemokines were generally significantly higher while the immunoglobulins were 
significantly lower in babies compared to their mothers (p<0.05). Results are not shown.  
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IL-2, IL-5, IL-7, IL-10, IL-12(p70), IL-13, IL-15, MCP-1 and VEGF concentrations in both mothers 
and infants were either OOR< or values were below LOQ. Immunoglobulins, IgG1, IgG3 and IgA 
concentrations were OOR> in both mothers and infants as the concentrations were higher than the 
ULD of the machine while some values were machine extrapolated as they were above the ULQ of 
the machine.  
 
One infant who did not have enteric pathogens isolated, seroconverted at 10 weeks and sample 
collected at 14 weeks had OOR> IgG1 and IgG3 whereas the mother had OOR< for both IgG1 and 
IgG3 and had viral load (VL) at recruitment was <20 copies-1. This mother had all the tested cytokines 
and chemokines concentrations that were very low, and mostly OOR<. Another baby that 
seroconverted at 6 weeks that had no identified enteric pathogens and whose sample was collected at 
10 weeks had OOR< immunoglobulins levels.   
 
 Cytokine and antibody responses in E. histolytica carriage. 
IL-1r, IL-4, IL-9, IL-12p70, IL-17a, G-CSF and PDGF-BB were significantly raised in E. histolytica 
compared to absence of E. histolytica in pregnant mothers (p<0.05) as shown Table 4-3a and Table 
4-3b. However, in babies, E. histolytica carriage had no significant impact on the cytokine and 
chemokine concentration as well as on immunoglobulin concentrations (p>0.05). 
Asymptomatic Enteric infection, Cytokine and antibody levels in pregnant mothers and their babies 
at delivery. 
Having any form of enteric infection carriage such as E. histolytica and non-lactose fermenters 
(NLFs) significantly increased the concentration levels for IL-1r, IL-4, IL-9, IL-10, IL-12p70, IL17a, 
G-CSF, GM-CSF, IFN-, PDGF-BB and TNF-α (p<0.05) as indicated in Table 4-4a and Table 4-4b. 
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However, there were no significant differences in terms of immunoglobulin levels under study 
between enteric infection carriers and non-carriers among pregnant mothers (p>0.05). In babies, the 
presence of varying enteric infections did not cause a significant difference in cytokine as well as 
immunoglobulin levels between enteric infection carriers and non-carriers in babies (p>0.05). 
 
Cytokine and antibody levels in relation to HIV infection in pregnant mothers and their babies 
IL-13 and G-CSF levels were significantly raised in HIV-infected pregnant mothers compared to 
HIV-uninfected pregnant mothers (p=0.0389 and p=0.0324 respectively) as shown in Table 4-5a and 
Table 4-5b. No significant differences were observed on immunoglobulin levels between these two 
groups.  In neonates, there was no significant difference in cytokine levels between the HEUs and 
HUUs. However, IgA immunoglobulin level was significantly raised among HEUs compared to 
HUUs (p=0.0282). Baby sex in pregnancy did not have significant effect on the pregnant mother’s 
cytokine or immunoglobulin levels (p>0.05).  
 
Baby cytokine and antibody levels in relation to birth weight  
IL-7 was significantly raised in low birth-weight babies (birth weight <2500g) compared to babies 
with >2500g birth weight (p=0.0149) as indicated in Table 4-6a and Table 4-6b. There was however 
no significant difference in immunoglobulin levels between ulow birth-weight and normal birth- 







DISCUSSION   
Generally cytokines and chemokines were significantly higher in babies compared to their mothers 
(p<0.05). MIP-1α concentration was however very low in both mother and infant sera. Infants had 
significantly higher IgG1 and IgG3 immunoglobulins compared to their mothers. Maternal IgG is the 
only immunoglobulin that crosses the placenta aided by the Fc receptors so their high concentrations 
in infants was expected. Maternal IgG is higher during gestation and begins to decrease at birth. As 
the maternal IgG lowers, the infant IgG begins to rise. At around 12 weeks (3 months) after birth, the 
mother and infant IgG concentrations intersect with the infant IgG concentrations, thereafter, rising. 
Thus, our observation at 14 weeks, is in concordance with previous research[3]. 
 
We report very low concentrations of IL-2, IL-5, IL-7, IL-10, IL-12(p70), IL-13, IL-15, MCP-1 and 
VEGF in both mothers and infants, this could be as a measure by the maternal immune system to 
control and escape fetal abortion. In fact an upregulation of IL-15 in trophoblasts are associated with 
recurrent abortions hence IL-15 could be used as a biomarker for pregnancy loss[23]. Szarka et al., 
(2010), has indicated that Th1 immunity in pregnancy is associated with increased IL-2/IL-4 and IFN-
/IL-4 ratios and that high levels of MCP-I was linked to pre-eclampsia in pregnancy. Also low levels 
of IL-12(p70) in relation to IL-12(p40) favoured Th2 immune responses in pregnancy[24]. As such, it 
is critical that these cytokines are monitored to maintain their low levels during pregnancy to prevent 
premature termination of pregnancies. 
 
We report that IgG4 occurred at low levels in both mothers and their infants. Literature has revealed 
IgG4 as a ‘promiscuous antibody, which could be directly pathogenic, fulfilling a protective role, or 
could just be a fortuitous marker of an aberrant inflammatory response’[25].  
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In addition, IgG4 antibodies possess exclusive structural and functional characteristics suggesting 
anti-inflammatory and tolerance-inducing effects[25]. The low concentration in our study may, 
therefore, be as a result of the body keeping check on the immunoglobulin concentration due to its 
potential to be directly pathogenic hence protecting the body from potential damage by IgG4 
immunoglobulin. Administering IgG4 drug in animal studies at onset of organogenesis and through 
delivery has been noted to elevate abortions as well as premature neonatal death. Data on humans is 
however scanty if not unavailable[26].  
 
In our study, one infant who did not have enteric pathogens isolated, seroconverted at 10 weeks and 
sample collected at 14 weeks had OOR> IgG1 and IgG3, whereas, the mother had OOR< for both 
IgG1 and IgG3. The mother also had viral load (VL) at recruitment of <20 copies/ml-1. Another baby 
that seroconverted at 6 weeks, had no identified enteric pathogens and its plasma sample was collected 
at 10 weeks. This baby had OOR< for the immunoglobulins tested. The mother VL at recruitment 
was 43 280 copies/ml-1. The observed low or no immunoglobulin production in the infant could be 
attributed to poor immune development of the baby in utero due to the compromised maternal 
immune system.  
 
In our study, IL-1r, IL-4, IL-9, IL-12p70, IL-17a, G-CSF and PDGF-BB were significantly raised in 
pregnant mothers with presence of E. histolytica infection compared to those with an absence of E. 
histolytica (p<0.05).  However, in babies, E. histolytica carriage seemed to have no significant impact 
on the cytokine and chemokine concentration as well as on immunoglobulin concentrations (p>0.05). 
Both IFN- and IL-17 provide protection against E. histolytica[27]. The finding on IL-17 corroborates 
findings in our study. However, IFN- was not raised which is conflicting to what Moonah et al., 
2013[27] found.  
 77 
 
This could be attributed to the fact that our study focused on asymptomatic carriage and not active 
disease hence speculatively, E. histolytica could have immune modulated the host to make sure it is 
not attacked by host immune responses.  
 
On the other hand, IFN- is usually produced against viral infections. This could be the reason why 
this cytokine was not raised in E. histolytica infections since E. histolytica is a protozoan parasite. It 
is plausible that in the study by Moonah et al., 2013, there were underlying infections that gave rise 
to the IFN- cytokine concentration. Babies seem to be protected somehow in utero, hence no 
significant rise of cytokine concentrations in infection observed in this study. 
 
In  pregnant mothers with an enteric infection carriage such as E. histolytica and Non-lactose 
fermenters (NLFs) significantly upregulated levels for IL-1r, IL-4, IL-9, IL-10, IL-12p70, IL17a, G-
CSF, GM-CSF, IFN-, PDGF-BB and TNF-α (p<0.05) was noted however but non significantly 
different in terms of immunoglobulin levels between enteric infection carriers and non-carriers 
(p>0.05). In babies, presence of any kind of enteric infection did not cause a significant difference in 
cytokine as well as immunoglobulin levels between enteric infection carriers and non-carriers in 
babies (p>0.05).  
 
The fact that IL-10, GM-CSF, IFN-, PDGF-BB and TNF-α were raised in E. histolytica infection in 
combination with other enteric pathogens and not in E. histolytica infection alone indicates that the 
upregulation of these cytokines is not as a result of E. histolytica but other underlying infections. This 
concurs with Bernin et al., (2014), since they observed low levels of IL-10 as well as raised IL-4 




In our study, IL-13 and G-CSF levels were significantly raised in HIV-infected pregnant mothers 
compared to HIV-uninfected pregnant mothers (p=0.0389 and p=0.0324 respectively). No significant 
differences were observed on immunoglobulin levels between these two groups.  In neonates, there 
was no significant difference in cytokine levels between the HEUs and HUUs. However, IgA 
immunoglobulin level was significantly raised among HEUs compared to HUUs (p=0.0282). IgA 
antibodies in mucosal secretions are directed against microbial antigens[28]. It is, therefore, possible 
that HEUs have opportunistic infections derived congenitally or from the environment which make 
HEUs have higher mortality and morbidity rates compared to HUUs, however, this warrants further 
investigation.  
 
IL-13 among other activities, down-regulates macrophage activity resulting in the inhibition of pro-
inflammatory cytokines and chemokines. IL-13 takes part also in B-cell maturation and 
differentiation[7; 14]. Speculatively, the significantly high concentration of IL-13 in HIV infection may 
be due to it down-regulating inflammatory cytokines due to HIV infection. We hypothesize that HIV 
pregnant women with low levels of IL-13 and G-CSF need a booster for these cytokines as the 
cytokines were from “healthy” HIV-infected pregnant mothers. This, however, needs further 
research. Speculatively, the significant high concentration levels of IL-13 in HIV-infected pregnant 
mothers is for immune regulation of inflammatory cytokines in a way to protect the developing baby 
in utero.  
 
The fact that G-CSF has been suggested as a reliable marker for use in neonates suffering from early- 
or late-onset of neonatal sepsis in previous studies[17] may also be true for HIV-infected pregnant 
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women. One of the functions of G-CSF is to stimulate production and proliferation of white blood 
cells[17–19]. 
 In this regard, it sounds logical that this cytokine was raised in HIV-infected pregnant women as 
white blood cells will be attacked and destroyed by the HIV virus in HIV infection, hence G-CSF 
will be needed in high concentration to replace the depleting white blood cells.  
 
Baby sex in pregnancy did not have significant effect on the pregnant mother’s cytokine or 
immunoglobulin levels (p>0.05). Our results, however, correlates to observations by Weissenbacher 
et. al., (2012) who could not find any correlation between baby sex and maternal cytokine 
production[29]. Contrary, Enninga et. al., (2015) observed an association between male fetal sex and 
pro-inflammatory cytokines specifically G-CSF, IL-12p70, IL-21, and IL-33 as well as angiogenic 
factors VEGF and PIGF while in female fetal sex regulatory cytokines IL-5, IL-9, IL-17, and IL-25 
were raised at multiple time points[13].  Our study did not look at multiple time points and also IL-21, 
IL-33 and PIGF hence might have contributed to these differences. IL-7 was significantly raised in 
under weight babies (birth weight <2500g) compared to babies with >2500g birth weight (p=0.01). 
There was, however, no significant differences in immunoglobulin levels between underweight and 
normal birth weight babies. IL-7 has been described as being involved in haematopoiesis and has 
been clinically used for a number of malignancies and in HIV infection[30].  
 
In conclusion, asymptomatic E. histolytica carriage results in up-regulation of IL-1r, IL-4, IL-9, IL-
12p70, IL-17a, G-CSF and PDGF-BB and the down-regulation of IL-10 and these can be possible 
markers for early E. histolytica infections before invasive infection.  
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Up-regulation of IL-13 and G-CSF can also be used to monitor HIV-infected pregnant mothers. 
Raised IL-7 can be used as a potential biomarker for the identification of small-for-gestational-age 
infants and the therapeutic effects for better management of the mother-baby pair. 
 
Study limitations and recommendations 
Samples were collected at just one study point and could have given a better insight if multiple data 
points were used. 
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Table 4-3a: Cytokine Median Concentration and Interquartile Ranges during E. histolytica infection 





Median cytokine concentrations  (pgml-1) in mother    p-value 
E. histolytica-infected E. histolytica-uninfected 
IL-1 3.54 (3.11-5.01) 3.045 (2.17-3.59) 0.1664 
IL-1r 204.07 (161.45-222.34) 140.89 (103.33-184.58) 0.0143 
IL-2 4.77 (1.99-8.55) 1.945 (1.54-3.98) 0.0859 
IL-4 10.28 (9.72-10.94) 8.95 (6.53-10.67) 0.0492 
IL-5 0 0.6 (0-0.6) 0.1491 
IL-6 9.11 (7.47-13.96) 7.95 (4.02-10.58) 0.1991 
IL-7 5.94 (1.1-12) 0 (0-3.27) 0.0762 
IL-8 27.22 (24.05-52.86) 20.63 (138-49.67) 0.1336 
IL-9 77.59 (73.33-96.42) 63.39 (43.44-73.83) 0.0214 
IL-10 6.53 (4.09-21.36) 4.055 (2.4-5.25) 0.0573 
IL-12 (p70) 8.87 (7.23-14.55) 6.155 (4.93-7.17) 0.0089 
IL-13 4.14 (2.21-12.28) 3.61 (0-10.58) 0.7866 
IL-15 3.22 (0-22.38) 0(0-3.72) 0.1204 
IL-17A 72.3 (67.87-89.95) 53.17 (41.13-66.51) 0.0051 
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Table 4-3b:Cytokine Median Concentration and Interquartile Ranges during E. histolytica infection 




Median cytokine concentrations  (pgml-1) in mother    p-value 
E. histolytica-infected E. histolytica-uninfected 
Eotaxin 26.04 (22.55-26.75) 22.484 (15.6-26.28) 0.2236 
FGF basic 63.56 (61.89-87.55) 50.295 (42.61-72.01) 0.0800 
G-CSF 65.4 (57.51-70.04) 54.48 (41.32-63.06) 0.0419 
GM-CSF 109.83 (104.05-165.91) 63.77 (8.08-127.01) 0.0663 
IFN- 212.07 (196.1-227.15) 176.355 (146.64-208.95 ) 0.0642 
IP-10 388.79 (332.62-435.8) 405.96 (309.89-669.72) 0.7389 
MCP-1 15.23 (10.62-23.27) 1.445 (0-15.48) 0.0873 
MIP-1α 7.19 (2.41-8.13) 2.63 (1.68-9.22) 0.4045 
MIP-1β 136.5 (131.05-185.6) 140.77 (87-230.25) 0.6892 
PDGF-BB 1591.6 (1156.45-1850.04) 1041.28 (732-1434.39 0.0455 
RANTES 2177.74 (1553.12-2369.24) 2185.455 (2074.41-2234.23) 0.9734 
TNF-α 41.44 (41.17-47.48) 38.29 (31.06-43.36) 0.1131 
VEGF 14.94 (8.63-16.5) 10.71 (8.07-15.33) 0.3952 
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Table 4-4a:Cytokine Median Concentration and Interquartile Ranges in relation to any type enteric 
of infection in pregnant mothers  
Cytokine name Median cytokine concentrations  (pgml-1) in mothers  p-value 
Infection  absent Infection present 
IL-1 3.045(2.1-3.58) 3.54(92.17-10.06) 0.1223 
IL-1r 130.39(102.03-182.745) 204.07(159.16-229.94) 0.0047 
IL-2 1.945(1.36-3.88) 4.77(1.85-12.62) 0.0702 
IL-4 8.895(6.625-10.17) 10.28(9.37-10.99) 0.0163 
IL-5 0.6(0-0.6) 0(0-0.6) 0.2892 
IL-6 7.95(4.02-10.05) 9.11(6.77-36.42) 0.1011 
IL-7 0(0-3.025) 5.94(0-13.56) 0.0524 
IL-8 17.295(13.395-48.075) 32.05(24.05-55.09) 0.0569 
IL-9 61.425(41.68-73.375) 77.59(72.74-98.51) 0.0080 
IL-10 4.055(2.4-5.095) 6.53(3.64-69.85) 0.0300 
IL-12 (p70) 6.155(5.285-7.045) 8.87(7.23-19.62) 0.0076 
IL-13 3.43(0-10.405) 4.14(2.21-13.15) 0.4101 
IL-15 0(0-2.92) 3.22(0-31.96) 0.0587 
IL-17A 50.425(37.845-65.995) 72.3(64.63-111.38) 0.0016 
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Table 4-4b: Cytokine Median Concentration and Interquartile Ranges in relation to any type of enteric 














Cytokine name Median cytokine concentrations  (pgml-1) in mothers  p-value 
Infection  absent Infection present 
Eotaxin 22.485(15.395-26.22) 26.04(20.43-32.91) 0.1261 
FGF basic 50.295(42.61-69.14) 63.56(43.31-107.6) 0.0510 
G-CSF 53.87(41.105-61.875) 65.4(55.9-150.08) 0.0192 
GM-CSF 63.77(5.26-124.215) 109.83(70.86-174.61) 0.0336 
IFN-ץ 176.355(141.315-207.375) 212.07(162.52-323.3) 0.0378 
IP-10 400.565(309.43-578.465) 408.02(332.62-734.86) 0.5957 
MCP-1 1.27(0-11.75) 15.23(0-30.75) 0.0652 
MIP-1α 2.54(1.65-9.73) 6.58(2.41-8.13) 0.3029 
MIP-1β 138.33(86.67-222.83) 147.15(131.05-333.38) 0.2886 
PDGF-BB 940.09(713.595-1421.46) 1591.6(1156.45-1850.04) 0.0246 
RANTES 2185.455(2075.905-2239.785) 2177.74(1553.12-2369.24) 0.8271 
TNF-α 37.06(30.79-42.4) 41.44(38.98-51.89) 0.0404 
VEGF 10.71(7.605-14.7) 14.94(8.44-54.94) 0.2545 
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Cytokine name Median cytokine concentrations  (pgml-1) in mother    p-value 
HIV-infected HIV-uninfected 
IL-1 2.7(1.76-3.57) 3.495(2.5-4.565) 0.1224 
IL-1r 126.83 (100.73-184.58) 156.08(112.3-221.99) 0.1939 
IL-2 1.9 (1.45-3.79) 2.515(1.66-5.515) 0.2364 
IL-4 9.65 (8.21-10.99) 9.155(6.895-10.515) 0.7075 
IL-5 0.6(0-0.6) 0.6(0-0.6) 0.9370 
IL-6 8.57(4.02-11.24) 8.77( 4.095-11.765) 0.8172 
IL-7 1.1(1.1-5.94) 1.835(1.1-6.55) 0.5431 
IL-8 22.81(14.61-58.26) 27.705(15.685-50.275) 0.7399 
IL-9 70.57(43.44-87.57) 69.82(51.54-81.425) 0.7950 
IL-10 2.8(2.12-5.25) 4.4245(3.605-10.9) 0.1058 
IL-12 (p70) 6.25(4-7.42) 6.92(5.79-8.93) 0.2601 
IL-13 2.21(0.7-6.05) 7.355(0.7-16.385) 0.0324 
IL-15 0 0(0-14.470) 0.0927 
IL-17A 64.63(34.56-70.26) 58.14(42.17-78.25) 0.6966 
 90 
 




    
Cytokine name Median cytokine concentrations  (pgml-1) in mother    p-value 
HIV-infected HIV-uninfected 
Eotaxin 23.4(15.19-26.28) 23.405(19.795-27.040 0.6032 
FGF basic 59.05(42.61-72.01) 52.025(43.135-75.025) 0.8852 
G-CSF 46.85(40.89-60.69) 59.895(53.87-72.325) 0.0389 
GM-CSF 79.62(11.22-141.25) 84.16(30.69-133.355) 0.9539 
IFN- 179.04(114.96-205.8) 192.76(156.855-231.49) 0.1888 
IP-10 435.8(343.44-829.12) 386.89(295.015-556.72) 0.1410 
MCP-1 5.03(0-19.04) 2.695(0-17.515) 0.8108 
MIP-1α 2.13(1.62-7.84) 4.075(1.985-9.38) 0.3555 
MIP-1β 109.21(78.4-215.41) 152.58(125.005-268.385) 0.1333 
PDGF-BB 1405.01(695.19-1733.99) 1107.48(859.83-1637.28) 0.7508 
RANTES 2203.05(1434.56-2369.24) 2177(2088.655-2226.125) 0.9081 
TNF-α 38.7(30.52-44.73) 39.66(32.965-44.46) 0.6965 
VEGF 9.67(6.77-11.85) 12.765(9.1-16.4) 0.0711 
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Table 4-6a: Maternal Cytokine Median Concentration and Interquartile Ranges in relation to infant 
birth weight 
  
Cytokine name Median cytokine concentrations  (pgml-1) in infants    p-value 
<2500g birth weight >2500g birth weight 
IL-1 6.52 (5.95-6.9) 5.205 (3.29-7.54) 0.3733 
IL-1r 240.87 (225.11-451.25) 170.1 (110.19-291.64) 0.1559 
IL-2 5.47 (3.55-8.55) 5.565 (2.26-1132) 0.9556 
IL-4 7.93 (6.55-11.93 ) 6.74 (4.35-10) 0.3733 
IL-5 30.24 (24.29-35.88) 4.4 (0-27.75) 0.0653 
IL-6 25.23 (14.85-31.76) 15.735 (10.45-24.640 0.2207 
IL-7 26.34 (23.84-30.76 ) 5.625 (0-1672) 0.0149 
IL-8 36.94 (33.01-37.37 ) 32.315 (18.73-56.12) 0.9114 
IL-9 70.25 (29.92-95.65) 66.585 (32.89-87.89) 0.9114 
IL-10 10.74 (10.06-13.05) 8.875 (5.88-13.19) 0.4695 
IL-12 (p70) 16.61 (16.26-19.55) 12.255 (8.1-23.5) 05779 
IL-13 16.21 (13.36-26.12) 11.83 (3.79-15.91) 0.1815 
IL-15 0(0-20.25) 0(0-12.88) 0.7618 
IL-17A 59.34 (29.7-114.25) 48.535 (23.08-83.85) 0.7596 
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Cytokine name Median cytokine concentrations  (pgml-1) in infants    p-value 
<2500g birth weight >2500g birth weight 
Eotaxin 42.13 (29.76-45.01) 25.15 (20.68-37.06) 0.1066 
FGF basic 85.51 (75.77-122.1) 74.9 (64.92-94.17) 0.3032 
G-CSF 97.33 (95.55-129.04) 74.595 (54.28-105.8) 0.1642 
GM-CSF 111.16 (68.06-238.08) 159.09 (113.38-190.2) 0.6165 
IFN- 367.74 (325.52-420.25) 243.575 (180.8-371.75) 0.1259 
IP-10 115.08 (264.34-1450.46) 575.445 (390.36-790.45) 0.4039 
MCP-1 25.46 (8.85-41.02) 16.57 (6.76-26.07) 0.3160 
MIP-1α 3.88 (3.07-4.14) 3.515 (2.48-6.81) 0.8674 
MIP-1β 203.82 (35.38-275.25) 188.79 (131.29-222.35) 0.9114 
PDGF-BB 423.89 (142.56-16.02.57) 327.1 (125.06-955) 0.6562 
RANTES 2161.44 (2100.87-2476.54) 2192.09 (2060.44-2305.17) 0.6969 
TNF-α 59.62 (51.34-74.59) 42.54 (32.42-67.92) 0.2538 
VEGF 36.28 (31.34-94.85) 35.81(19.06-75.91) 0.5779 
 93 
 
Chapter 5 : Determination of the association between maternal characteristics that affect the 
cytokine responses of their neonates  
 
The last chapter identified maternal and infant cytokine profiles that were important during pregnancy 
and infection. The question that remains is how these significant cytokines and immunoglobulins 
affect the cytokine and immunoglobulin production in infants in the mother –infant pairs. In trying to 
answer the question, a manuscript entitled ‘Influence of maternal characteristics during pregnancy on 
the infant early life immune responses in a high HIV prevalence setting in Harare, Zimbabwe’ was 
developed and is under review in the African Jounal of Reproductive Health (AJRH). Proof of 
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The study aimed at investigating the maternal characteristics that in turn influence the immunological 
status of the infant in asymptomatic enteric pathogen carriers in mother infant pairs in a high HIV 
burdened population in Harare, Zimbabwe.  
Methodology 
A Bioplex immunoassay was used to analyse serum samples from 39 mother-infant pairs (MIP) for 
27 cytokines and 6 immunoglobulins. The MIP were purposively selected based on HIV infection 
and E. histolytica carriage. Logistic regression was used to identify any link between maternal 
demographic and clinical data with infant cytokine and immunoglobulin levels.  
Results 
 Maternal E. histolytica carriers are more likely to have infants with low levels of IL-12p70, FGF-
basic, GM-CSF and TNF-α cytokines (OR: 0.14; 95% CI: 0.03-0.79) and high levels of IgA 
immunoglobulin (OR: 8.1; 95% CI: 1.45-45.06). HIV-infected mothers are more likely to have infants 
with low levels of IgG2 (OR:  0.24; 95% CI: 0.06-1.00) and IgA (OR: 0.22; 95% CI: 0.05-0.90) 
immunoglobulins. Mothers giving birth at a mean age above 30.38 years (Standard deviation ±6.09) 
are more likely to have infants with low IgG4 levels (OR:  0.24; 95% CI: 0.06-1.02) albeit borderline  
significant (p=0.05).  
Conclusion 
Maternal E. histolytica asymptomatic carriage, age and HIV status need to be monitored to avoid 





Significance and impact of study  
The study was a culmination to the need to consider maternal characteristics such as age, HIV status, 
immunological status and enteric pathogen carriage in pregnancy as these might impact on their 
infants’ immune development and responses. This will assist in the disease treatment and prevention 
management of pregnant women decision and might assist in developing effective immunotherapy 
for reducing autoimmune diseases in HIV-exposed uninfected infants.  
Key words 






Despite the success of HIV prevention of mother to child transmission (PMTCT) programs in 
Zimbabwe, there still exists an increased burden in mortality and morbidity of the HIV-exposed 
uninfected (HEU) compared to HIV-unexposed infants (HUUs). The frequent pattern of morbidity 
and mortality in HEUs correlates to diarrheal disease, pneumonia and bacterial sepsis which are the 
most frequent causes of childhood morbidity and mortality, however, the actual cause is still 
insufficiently defined [1].  
 
Exposure of the infant to maternal environmental factors such as viral, bacterial, parasitic and other 
factors impact on fetal innate and adaptive immunity development. There is paucity of information 
with regards to the relationship between maternal characteristics and the infant immune responses.  
In this study we hypothesize that maternal factors such as age, ethnicity, alcohol uptake, probiotic 
uptake, asymptomatic carriage of enteric pathogens, HIV status as well as immunological status 
influences the infant’s immunological response based on cytokine and immunoglobulin levels.  
 
Infants are highly susceptible to infectious diseases possibly due to immaturity of their immune 
system and susceptibility to tolerogenic signals. At an early stage of life, infant antigen presenting 
cells and CD4 T cells were found to display reduced ability to produce cytokines as well as cytokine 
receptors, which may result in decreased cytotoxic effector cell function and a decreased ability to 
provide adequate B-cell assistance[2]  affecting the high  susceptibility to infections. Individuals that 
are asymptomatically infected with E. histolytica could represent an important group enabling the 
study of immune responses that are critical to the outcome of an infection [3].  
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In this study, we focus on maternal demographic and clinical factors implicated in cytokine and 
immunoglobulin production in infants within a HIV burdened setting. 
 
MATERIALS AND METHODS 
Ethics approval and consent to participate 
The approval for this study was granted by the Medical Research Council of Zimbabwe, Approval 
Code MRCZ/A/2043 as well as the Biomedical Research Ethics Committee (BREC) of the University 
of KwaZulu-Natal, Durban, South Africa, Approval Code 409/15.  Consent to take part in the study 
was granted by the study participants.   
 
Study population and sampling 
This was a sub-study based on stored plasma samples collected from the University of Zimbabwe- 
College of Health Sciences Birth Cohort of HIV-infected (HIV+) and HIV-uninfected (HIV-) pregnant 
women. Samples were collected during the period February 2016 to February 2017.  The main study 
was approved by the Medical Research Council of Zimbabwe, approval code MRCZ/1948 and the 
Joint Research Ethics Committee, approval code JREC81/15. The study participants were from 
Dzivarasekwa, Glenview and Kuwadzana, three high-density suburbs in Harare, Zimbabwe, based 
on previous burden of pathogens of interest. The mothers recruited in this study were between 18 and 







The pregnant women on their routine antenatal care visits were invited to participate in the study. 
After agreeing, an informed consent form was administered and signed by participant and the 
interviewer before a questionnaire administration to capture demographic data such as HIV status, 
ART uptake and regimen. The mothers were followed up to delivery where information on delivery 
mode, infant sex and weight, as well as infant HIV statuses, were taken and infant blood collected for 
sera where possible.  
 
Those mother-infant pairs (MIP) who were able to provide stool samples had cultures and ELISA 
done on the samples. The MIPs that had E. histolytica, as well as other enteric pathogens detected, 
were considered for cytokine and antibody profiling 
Biomedical samples collected 
Stored sera for 39 MIPs were purposively selected based on Entamoeba histolytica infections and 
other microbial infections as well as maternal HIV status results based on the outcome of the 
screening process of this study. Controls were based on lack of enteric pathogens and also being HIV 
negative. Maternal prenatal samples were obtained on recruitment and for infant the sera were as 
close to delivery as possible.  The majority of infant samples were collected at 14 weeks and 6 weeks 
as shown in Table 5-1. 
Table 5-1: Summary of the serum sample collection points for infants used in the study 
Serum point of collection Frequency Percentage 
10 days 4 10.26 
30 days 1 2.56 
6 weeks 15 38.46 
10 weeks 4 10.26 
14 weeks 15 38.46 




Cytokine and chemokine profiling 
All the 39 MIP were analysed using Bio-plex Pro Assay 27 plex kit, Bio-Rad, USA. The 27 cytokines 
and chemokines investigated were IL-1β, IL-1r, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12p70, IL-13, IL-15, IL-17a, Eotaxin, basic PDGF, G-CSF, GM-CSF, IFN-, IP-10, MCP-1(MCAF), 
MIP-1α, MIP-1β , PDGF-BB, RANTES, TNF- α and VEGF. A total of 27 serum cytokines were 
multiplexed using this magnetic-bead based multiplex immunoassay according to the manufacturer’s 
instructions.  
The plate washings were performed on a Bio-Plex Pro and Bio_Plex Pro 11, Revision B, wash station 
and incubations were performed at room temperature on a Bio-Rad Shaker Fax – 2200. Bio-Plex® 
200 system (Bio-Rad, California, USA) which uses Bioplex Manager Software was used for Data 
acquisition which gave out data output as Median Florescence Intensity and concentration in pgml-1. 
In this study, only those cytokines which were analysed to have significance were further analysed to 
see the maternal influences on the infant immune responses linking to maternal characteristics. 
Cytokines and Data Analysis 
Cytokine analysis was done to observe the influence of maternal factors such as age, HIV status, E. 
histolytica carriage, tribe and area of residence on the infant immune response based on the levels of 
the 27 cytokines and 6 immunoglobulins tested.  Data analysis was based on logistic regression to 
determine any associations between maternal characteristics and infant cytokine and immunoglobulin 
production.  During analysis, MIP outliers per variable were dropped irrespective of whether the 







The maternal mean age ±standard deviation (SD) was 30.38± 6.09 years and were equally distributed 
amongst the three residential suburbs. Twenty-four of the mothers were HIV negative and 15 were 
HIV positive. Of the 15 HIV positive, 14 were on Antiretroviral Therapy (ART) and the other one 
aged 24 years stated that the husband refused her to take medication. Out of the 14 on ART, 12 were 
on Telonam E, 1 on Telonam N and 1 did not indicate her ART regimen.  
 
Sampling and sample collection 
A total of 39 MBP who had cytokines and antibody profiling performed were considered for this 
study.   Approximately 38.5% of the mothers were HIV positive and 61.5% were HIV negative based 
on HIV rapid tests. Of the 39 mothers, 23.1% had E. histolytica infection.  Of the 39 babies, 
12(30.8%) were HIV-exposed uninfected (HEUs), three (7.7%) were sero-converters and 24 (61.5%) 
were HIV-unexposed uninfected (HUUs). A total of 8 (20.5%) infants had E. histolytica infections 
of which 5 were HUUs and 3 were HEUs. No enteric pathogen was isolated in the three babies who 
sero-converted.  
 
Influence of maternal E. histolytica carriage on infant cytokine and immunoglobulin levels 
None of the maternal demographic characteristics analysed seemed to have an influence on the infant 
cytokine production levels (p>0.05). Maternal E. histolytica carriage seemed to significantly 
(p=0.026) influence infant Interleukin (IL)-12p70, Fibroblast Growth Factor-basic (FGF-basic), 
Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF) and Tumor Necrosis Factor (TNF)-α 
cytokines. The odds of having high levels of these cytokines in infants is reduced by 86% if the 
mother is a carrier of E. histolytica during pregnancy (OR: 0.14; 95% CI: 0.03-0.79; Table 5-2a and 
Table 5-2b).  
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Immunoglobulin (Ig)A also appear to be significantly influenced (p=0.017) by maternal E. histolytica 
carriage. An infant born to a mother with E. histolytica carriage has 8.1 odds of having high levels of 
IgA greater than an infant born to a mother without E. histolytica carriage (OR: 8.1; 95% CI: 1.45-
45.06; Table 5-3). 
 
Influence of maternal HIV infection on infant cytokine and immunoglobulin production 
Maternal HIV infection did not seem to influence infant cytokine production levels (Results not 
shown). However maternal HIV infection seems to influence infant IgG2 and IgA immunoglobulin 
levels. Infants born to HIV positive mothers are significantly associated (p=0.049) with lower odds 
of having high IgG2 levels, that is the odds of having high IgG2 immunoglobulin levels is reduced 
by 76% in infants born to HIV-infected mothers compared to those born to HIV-uninfected mothers 
(OR:  0.24; 95% CI: 0.06-1.00) . Similarly, an infant born to a HIV-infected mother is significantly 
associated (p=0.035) with lower odds of having high IgA immunoglobulin levels compared to the 
one born to HIV-uninfected mothers (OR: 0.22; 95% CI: 0.05-0.90) as shown in Table 5-3.  
 
Influence of maternal age on infant cytokine and immunoglobulin production 
Maternal age did not influence infant cytokine levels (results not shown) but affected the infant IgG4 
immunoglobulin levels. Being born to a mother above mean age± standard deviation of 30.38± 6.09 
years reduces the odds of having high IgG4 compared to those born to mothers below 30.38± 6.09 




DISCUSSION   
The need to improve maternal and child well-being is one of the millennium development goals which 
is critical in public health since it affects the general health of the next generation.  It is generally 
accepted that maternal immunity influences the infant immune development. This study demonstrates 
how maternal demographic and clinical variables influences infant cytokine and immunoglobulin 
levels.   
 
This study shows that maternal E. histolytica carriage is a strong confounder for infant IL-12p70, 
FGF-basic, GM-CSF and TNF-α cytokines production levels and IgA immunoglobulin levels. There 
are conflicting evidences on the function of TNF-α during amoebic infections. Some studies have 
indicated TNF-α to have a protective effect against E. histolytica infection while others indicated an 
increased susceptibility of the host to E. histolytica infection in the presence of TNF-α [5].It was also 
observed that TNF-α blocking agents lead to healing of tissue inflammation in gastro-enteric diseases 
such as inflammatory bowel diseases (IBD) [4]. Also Zhang et al., [5] have noted that TNF-α blocking 
agents reduces inflammation and intestinal damage in amebic infection, while inhibition of IL-1 
reduced cytokine production but had less marked effects on inflammation and disease.  
 
In this regard, the reduced levels of the cytokine in infants born to E. histolytica carriers may mean 
that the parasite produces the blocking agents to TNF-α release to avoid destruction by the host, and 





Speculatively, the low TNF-α levels in infants born to mothers with E. histolytica carriage maybe 
also due to the immune modifications on the maternal TNF-α gene so that the TNF-α cytokine is 
produced in low concentration to avoid destruction. The defected cytokine genes might be genetically 
passed on to the infants since the cytokine genes can be inheritable[4,6].  
 
GM-CSF is basically a hematopoietic and myelopoietic growth factor[7,8] which also promotes 
production of pro-inflammatory cytokines such as TNF-α, IL-6, IL-12p70, IL-23 and IL-1β as well 
as chemokines like CCL22, CCL24, CCL5 and CCL1 which promote leukocyte recruitment[7]. Thus 
we expect this cytokine to be elevated in infection. In our study, this cytokine was in low levels in 
infants born to E. histolytica carriers which might explain one of the strategies by E. histolytica to 
evade the host immune response. Possibly the parasite will modulate the host immune system leading 
to downregulation of GM-CSF which eventually results in less leukocytes to fight the parasite. Since 
the GM-CSF production will be down-regulated in the mother, we expect the infant to also have low 
level of the cytokine. In addition, GM-CSF has a role in the production of TNF-α and IL-12p70, Since 
GM-CSF was down-regulated, it is not surprising that the latter 2 cytokines were low. 
 
FGF-basic has not been well studied in asymptomatic E. histolytica carrier pregnant mothers hence 
there is limited data in this regard. There is need for more research on the relationship between this 
cytokine with asymptomatically infected E. histolytica maternal carriers and their infants. FGF-basic 
has been shown, amongst other factors, to promote healing of wounds and reduction of scars although 
it is still not clear how this occurs at a molecular level[9]. As such, this cytokine is expected to be in 




E. histolytica pathogenesis involves development of a “flask shaped” ulcer [10] which the host has to 
heal. In chronic infections, the amoeba will have learnt to live with the host hence there is possibly 
remarkable reduction in host damage hence the reduced concentration of FGF-basic, which will be 
transferable to the infant.  
 
The raised IgA immunoglobulin levels in infants born to E. histolytica carriers observed in this study 
correlates to findings by Nakada-Tsukui and Nozaki, who have indicated an increase in IgA 
transportation across the intestinal epithelium and promotion of neutrophil infiltration[11] in the 
presence of E. histolytica infection. The infants might, therefore, be exposed to this immunoglobulin 
during breastfeeding, and if infected due to exposure to the infected mother, will also start producing 
their own IgA immunoglobulins. It was shown that HIV-infected mothers are more likely to have 
infants with low levels of IgG2 and IgA immunoglobulins from this study. This finding is in 
concordance with results from Abu-Raya et al., [12] who, in their review, indicated the capability of 
HIV infection to alter the transfer of maternal immune factors to the exposed newborns and young 
infants. This may relate to the immune activation in HIV-infected pregnant women, associated with 
the production of inflammatory cytokines at the maternofetal interface associated with inflammatory 
responses in the newborn [12].   
 
It has also been noted by earlier studies that the immunoglobulin IgG is the only antibody class 
capable of significantly crossing the placenta which is highly dependent on the (i) maternal levels of 
total IgG and specific antibodies, (ii) gestational age, (iii) placental integrity, (iv) IgG subclass, and 
(v) nature of antigen [13]. As such, since HIV infection has a negative impact on the immune cells 
production, it is possible that it reduces the IgG2 production in the pregnant mothers which effectively 




We also observed that mothers giving birth at a mean age 30.38± 6.09 years are more likely to have 
infants with low IgG4 levels.  This study finding is a contrast to the findings by Lamb et al., who 
found an association between higher gluten IgG4 with older age in their study on association of IgG4 
with dietary factors[13]. Maybe this is because these IgG4 immunoglobulin were specific to gluten. 
Palmeira et al., found no influence of ‘maternal age, weight, parity and type of delivery’ on ‘placental 
antibody transfer’[14]. Our study, however, was not looking at placental antibody transfer but on the 
influence of maternal characteristics on the infant immunoglobulin and cytokine levels. We, 
therefore, speculate that as one gets older, so do immune cells.  It is well accepted that with advanced 
age, the immune system undergoes profound re-modelling and decline, with major impact on health 
and survival of the individual [15]. So with age, it is possible that maternal IgG4 was now produced in 
low concentrations which were also transferred in low concentrations in utero or postpartum via 
breast milk.  
 
The wide confidence intervals observed in this study are more likely due to the small sample size 
used for this particular study, i.e, 39 mother-baby pairs. Individual immune response differences may 
be influenced by cytokine gene polymorphisms.  
 
In conclusion, it is critical to encourage mothers to consider child-bearing at younger age avoid the 
negative influence of maternal age on infant immunoglobulin levels. Also maternal HIV status result 
in low levels of IgG2 and IgA in infants while E. histolytica carriage result in high levels if IgA in 




Study limitations and recommendations 
The observed trends in this study between the relationships of maternal characteristics and their 
neonates which were not significant might indicate true possibility of these trends if sample size was 
increased. This study only used 39 mother-infant pairs (MIP) due to financial constraints. This 
resulted in a further reduction in the quantification characteristics under study, making some analysis 
not statistically sound, hence the need to carry out the research at a larger scale. The results, however, 
provide some insight in the area of study. Also, samples were collected at just one study point and 
could have given a better insight if multiple data collection points were used. 
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Table 5-2a: Influence of Maternal E. histolytica carriage on Infant Cytokine Concentration Levels 
 
Infant Cytokine Maternal   E. histolytica carriage 
Odds Ratio P-value 95% Confidence 
Interval 
IL-1b 0.5 0.337 0.12-2.08 
IL-1r 0.5 0.337 0.12-2.08 
IL-2 0.83 0.798 0.21-3.38 
IL-4 0.83 0.798 0.21-3.38 
IL-5 0.27 0.08 0.06-1.17 
IL-6 0.28 0.103 0.06-1.29 
IL-7 0.7 0.636 0.16-3.1 
IL-8 0.34 0.176 0.07-1.61 
IL-9 0.83 0.798 0.21-3.38 
IL-10 0.34 0.176 0.07-1.61 
IL-12 (p70) 0.14 0.026 0.03-0.79 
IL-13 0.5 0.337 0.12-2.08 
IL-15 0.57 0.445 0.14-2.40 
IL-17A 0.83 0.798 0.21-3.38 
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Table 5-2b: Influence of Maternal E. histolytica carriage on Infant Cytokine Concentration Levels 
 
Infant Cytokine Maternal   E. histolytica carriage 
Odds Ratio P-value 95% Confidence 
Interval 
Eotaxin 0.28 0.103 0.06-1.29 
FGF basic 0.14 0.026 0.03-0.79 
G-CSF 0.28 0.103 0.06-1.29 
GM-CSF 0.14 0.026 0.03-0.79 
IFN- 0.28 0.103 0.06-1.29 
IP-10 0.5 0.337 0.12-2.08 
MCP-1 mcaf 0.21 0.113 0.03-1.45 
MIP-1α 0.49 0.335 0.12-2.08 
MIP-1β 0.5 0.337 0.12-2.08 
PDGF-BB 0.83 0.798 0.21-3.38 
RANTES 0.28 0.103 0.06-1.29 
TNF-α 0.14 0.026 0.03-0.79 






Table 5-3: Influence of Maternal E. histolytica carriage, HIV infection and Age on Infant Immunoglobulin Concentration Levels 
Infant 
Immunoglobulin 
Maternal HIV Infection Maternal Age Maternal   E. histolytica carriage 
Odds  
Ratio 








P-value 95% Confidence 
Interval 
IgG1 1.35 0.649 0.37-4.92 0.58 0.422 0.15-2.21 2.3 0.248 0.55-9.83 
IgG2 0.24 0.049  0.06-1.00 1.27 0.729 0.33-4.97 2.2 0.288 0.52-9.27 
IgG3 0.88 0.839 0.24-3.18 0.92 0.898 0.24-3.46 1.4 0.649 0.34-5.62 
IgG4 0.4 0.183 0.10-1.55 0.24 0.050 0.06-1.02 2.2 0.288 0.52-9.27 
IgA 0.22 0.035 0.05-0.90 1.1 0.898 0.29-4.12 8.1 0.017 1.45-45.06 





CHAPTER 6: SYNTHESIS  
 
6.1   General Overview 
 
The final chapter of this thesis provides a comprehensive analysis of the findings, giving an indication 
of prevalence of asymptomatic enteric pathogens in pregnant women and their neonates, highlighting 
possibilities of congenital transmissions of enteric pathogens, and to understand the effect of 
asymptomatic enteric pathogens on the cytokine and antibody levels in the mother-infant pairs as well 
as the influence of maternal demographic and clinical variables on infant cytokine and 
immunoglobulin production.  
  
6.2 Microbial analysis 
 
In this study, microbial results demonstrated no prevalence of asymptomatic carriage of S. typhi and 
V. cholerae in both maternal and infant population. This absence may be attributed to either to the 
rareness of the long term convalescent V. cholerae carrier [62] or to the possible lack of detection of 
the S. typhi and V. cholerae pathogens during culture.  It is worthy to mention stool used for culture 
was a once off collection and may have contributed to reduced sensitivity of isolation. Similar finding 
was also obtained by Im et al., (2016) who also obtained a 0% isolation of S. typhi from over a 
thousand stool cultures from two different countries [61].  
 
We report that E. histolytica asymptomatic carriage was 5.4% in the pregnant mothers and 5.6% in 
the infants which indicates a reality of asymptomatic E. histolytica carriage in pregnancy and at 
infancy. The possibility of congenital transmission of E. histolytica was also observed and this might 
call for the inclusion of such a pathogen on the TORCH (T = Toxoplasmosis / Toxoplasma gondii, O 
= other pathogens, R = Rubella, C = Cytomegalovirus and H = Herpes Simplex Virus) series where 
it could be added as the ‘Other’ of the ‘TORCH’ series. There is therefore a need to screen pregnant 
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women to prevent congenital transmissions of E. histolytica to the new-borns as well as screen new-
borns for early intervention before the onset of a serious infection. Usually maternal parasitic 
infections are asymptomatic [114] and if total hygiene is not practised during breastfeeding, the mother 
can unknowingly transmit the protozoan to the infant. 
 
6.3 Immunological Analysis 
Chronic amoebiasis will result in the host developing an immune response that does not enable it to 
eliminate the tissue resident parasite and at the same time the parasite will be intensively 
immunosuppressing the host [115]. Asymptomatic carriers thus have a depressed immune reactivity to 
the infecting parasite [116]. 
 
Using an immunological analysis, this study reports an increased level of production of IL-5 in HEUs 
compared to HUUs albeit none significantly (p=0.6973). IL-5 together with IL-3 and GM-CSF has 
been verified by earlier studies to be important in the regulation of eosinophil development, although 
IL-5 is the most specific for eosinophil differentiation and release from bone marrow into the 
peripheral circulation. The three eosinophilpoetins are coded by closely linked genes on human 
chromosome 5q31[117]. 
 
Notably the significant upregulation of IgA in the HEUs compared to HUUs in our study may be 
linked to the raised IL-5 production observed in HEUs. IL-5 has been seen to be important in mucosal 
IgA which is mainly in the mucosal tissue where it provides defence from ingested and inhaled 





Generally, HIV burden in pregnancy has been shown to significantly increase the IL-13 and G-CSF 
production which has been attributed to the critical need of these proteins in infection. IL-13 also has 
an anti-inflammatory effect. G-CSF is required for white blood cell production to fight the virus and 
other opportunistic infections. E. histolytica infections in our study was shown to stimulate the 
production of IL-1r, IL-4, IL-9, IL-12p70, IL-17a, G-CSF and PDGF-BB. Similarly, Guo et al., 
(2009) report elevated levels of IL-12 and IL-17 in addition to IFN-, IL-2 and IL-10 [56], which were 
not significantly raised in our study.   
 
The up-regulation of IL-9 in E. histolytica infections is concurrent with reports from Licona-Limon 
et al., 2017, who have indicated its role in immune responses to parasitic infection in addition to its 
importance in allergic diseases like asthma and bronchial hyperactivity [120]. Chronic parasitic 
infections call for the host to effectively balance the immune response.  
 
There is also growing evidence that the dominant Th2 cytokines such as IL-4 (which is usually co-
produced with IL-13) and IL-10 may reduce disease severity hence enhance host survival [121]. Despite 
implications of Th2 responses in immunopathology, cytokines such as IL-4 and IL-13 can enhance 
host survival in chronic parasitic infections as well as providing protection from superinfections [120; 
122]. So, the observed up-regulation of IL-4 may be due to the asymptomatic and probable chronic 
nature of the E. histolytica infection in the study population.  
 
The increased concentration of PDGF-BB in E. histolytica infection may be attributed to the need to 
regenerate cells damaged by the parasite[123]. IL-17A is critical in neutrophils recruitment to site of 
infection [124] and this may explain the raised IL-17A observed in E. histolytica infection in our study. 
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Neutrophils conjugated with antigen presenting cells and will, however, be trogocytosed by E. 
histolytica as one of its defence mechanism against host immune response [47].  
 
It is important therefore to consider these as inflammatory markers of asymptomatic E. histolytica 
infection which could be used to diagnose such infections in pregnancy and new-borns before the 
negative effects on pregnancy outcome and well-being of the mother and the infant. It is also 
important to note the possibility of E. histolytica congenital transmission according to the results from 
this study, and this will obviously influence maternal and infant immune responses negatively hence 
the need to continuously monitor the parasite in pregnancy to reduce congenital transmission.  
 
Our study provides the first report of a probable E. histolytica congenital transmission. This, however, 
need to be verified at a larger scale. E. histolytica has surface galactose-N-acetyl-D-galactosamine 
inhibitable lectin (Gal-lectin) that is immunogenic and acts as a protective antigen. Gal-lectin has 
been indicated to induce Th1 cytokines, including IL-12, but the knowledge of the basis on which 
Gal-lectin provides protective immunity is scanty or unknown [45] hence there is need for further 
investigation.  
 
6.4 Maternal determinants of infant immunological responses 
This study examined the cytokines that were significantly raised in HIV infection, E. histolytica 
infection and infection by other enteric pathogens and their influence on the infant immune response.  
We report that IL-12p70 was significantly up-regulated in E. histolytica infection in mothers, whilst 
IL-13 and G-CSF were significantly up-regulated in HIV infection in pregnant mothers whilst IL-10, 
GM-CSF, IFN-  and TNF-α were raised in other enteric infections. IL-13 plays a dominant role in 




Maternal demographic and clinical variables were also analysed for their influence on the infant 
cytokine and immunoglobulin concentration levels but demographic factors seem to have no 
influence. This study has shown that maternal E. histolytica carriers are more likely to have infants 
with low levels of IL-12p70, FGF-basic, GM-CSF and TNF-α cytokines and high levels of IgA 
immunoglobulin. 
 
Interestingly, this study also demonstrates a significant elevation of IL-12p70 in maternal E. 
histolytica carriers, however, infants born to these mothers were likely to have low IL-12p70 cytokine 
concentrations levels compared to those born to maternal non-E. histolytica carriers. This might 
implicate some in-utero protection of the infants from E. histolytica infections, however, there is need 
for further investigation. There is also growing evidence that infants born to mothers with parasitic 
infections will develop lesions in their immune systems leading to tolerance or allergy as well as 
potential psycho-neurological changes leading to disease [89].  
 
HIV-infected mothers are more likely to have infants with low levels of IgG2 and IgA 
immunoglobulins. It is highly possible that HIV alters the maternal immunoglobulin production levels 
which will eventually be passed on to the infant in utero or during breastfeeding. Franca et al., (2012) 
have realised a similar trend whereby they found out that immunoglobulin levels were lower in 
hyperglycemic compared to normoglycemic mothers [127].   
 
 
We also report that mothers giving birth at a mean age above 30.38± 6.09 years are more likely to 
have infants with low IgG4 levels (p=0.05). Speculatively, since immune cells also age as one gets 
older, there is a high probability that giving birth at an older age will also transfer weaker immunity 




6.5 Conclusion   
 
This study demonstrates an E. histolytica prevalence of 5.4% in mothers and 5.6% in infants with an 
absence of V. cholerae and S. typhi detection in the areas of Dzivarasekwa, Glenview and Kuwadzana 
in Harare, Zimbabwe. Notably we report a similarity in the prevalence of E. histolytica between HIV-
infected and HIV-uninfected mothers (p=0.318). Similarity in E. histolytica prevalence was also 
noted between HIV-exposed uninfected and HIV-unexposed uninfected infants though borderline 
non-significant (p=0.056).  Moreover, resistance to 3rd generation cephalosporines, was detected in 
the non-lactose fermenting bacterial isolates. Only one HIV-uninfected mother-infant pair had an E. 
histolytica infection.   
 
IL-1r, IL-4, IL-9, IL-12p70, IL-17a, G-CSF and PDGF-BB levels were significantly raised in E. 
histolytica infected compared to non-infected lactating mothers (p<0.05). In babies, E. histolytica 
carriage had no significant impact on the cytokine and immunoglobulin concentration. Carriage of 
any form of enteric infection such as non-lactose fermenters in addition to E. histolytica significantly 
increased concentration levels of IL-1r, IL-4, IL-9, IL-10, IL-12p70, IL17a, G-CSF, GM-CSF, IFN-
, PDGF-BB and TNF-α cytokines (p<0.05) but no significant differences in immunoglobulin levels 
among the mothers. IL-13 and G-CSF levels were significantly raised in HIV-infected compared to 
HIV-uninfected lactating mothers (p=0.0389 and p=0.0324 respectively). IgA immunoglobulin levels 
were significantly raised among HIV-exposed uninfected than HIV-unexposed uninfected infants 
(p=0.0282). IL-7 was significantly raised in low birth-weight babies (birth weight <2500g) compared 





Maternal HIV infection influences infant IgG2 and IgA immunoglobulin levels. Also a maternal age 
of >30years reduces the odds ratio of passing high IgG4 to the infant (p=0.05). Maternal HIV 
infection influences infant IgG2 and IgA immunoglobulin levels. Infants born to HIV positive 
mothers are significantly associated (p=0.049) with lower odds of having high IgG2 levels, ie., 
reduced by 76% in infants born to HIV-infected mothers compared to those born to HIV-uninfected 
mothers. Similarly, an infant born to a HIV-infected mother is significantly associated (p=0.035) with 
lower odds of having high IgA immunoglobulin levels compared to those born to HIV-uninfected 
mothers (OR: 0.22).  
 
In this study maternal E. histolytica carriage was significantly (p=0.026) correlated with infant 
Interleukin-12p70 (IL-12p70; p<0.026), Fibroblast Growth Factor-basic (FGF-basic; p<0.026), 
Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF; p<0.026) and Tumor Necrosis Factor 
(TNF; p<0.026)-α. The odds ratio of passing high levels of these cytokines to infants is reduced by 
86% if the mother is a carrier of E. histolytica during pregnancy (OR: 0.14). 
 
Finally, parasitic infections in pregnancy such as E. histolytica are a reality and there is real need for 
screening in pregnancy. The probability of congenital transmission of E. histolytica was noted in this 
study, highlighting the need to screen of infants at birth hence avoiding the negative influence of this 
pathogen in infants, families and the community. Amoebiasis is usually not implicated in new-
borns[128],  however, we advocate screening of this parasite in new-borns. Infections during pregnancy 
may guide vaccine production for treating pregnant mothers as well as their neonates. It is also critical 
to monitor maternal HIV status and E. histolytica carriage and encourage mothers to deliver at ages 
below 30 years as these eventually modulate the infant immune development.   
 120 
 
This infant immune modulation might possibly lead to development of auto-immune diseases and a 
possible cause of the observed high mortality and morbidity rates in HEUs. Further research is needed 
to confirm this. The current lack of E. histolytica vaccine[46] really calls for intensive studies in 
immune responses towards this parasite in an effort to assist development of vaccines and cytokine 
therapy for this devastating protozoan parasite. 
 
6.6 Study Limitations 
The study did not look at concurrent infections (except TB of which none of the study population was 
on TB treatment), vaccinations, concurrent treatment regiments (except antibiotics and antacids), 
nutritional status (except for probiotic uptake) and hospitalisation. These factors also influence one’s 
immune response. As such, results emanating from this study should be taken as preliminary findings 
to shape future research 
 
6.7 Recommendations 
Deduction from the general findings of the study recommend carrying out a larger scale study on 
immunology that would provide meaningful findings that can be extrapolated to the situation 
happening in Harare, Zimbabwe, with frequent outbreaks of S. typhi and V. cholerae.  The results 
reported in this thesis provide important preliminary results to shape future studies. Most studies are 
carried out on the diseased population neglecting the most important component of asymptomatic 
carriers, who, if left unnoticed, will spread diseases unknowingly and in some cases result in 
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CHAPTER 8: APPENDICES 




Regression Type: Logistic - 5PL 
Std. Curve: FI = 9.85531 + (27759.8 - 9.85531) / ((1 + (Conc / 215.761)^-8.58709))^0.128959 
FitProb. = 0.1360, ResVar. = 2.2227 
 
 
Regression Type: Logistic - 5PL 
Std. Curve: FI = 8.20982 + (30550.6 - 8.20982) / ((1 + (Conc / 1137.73)^-2.23834))^0.494722 
FitProb. = 0.7118, ResVar. = 0.3400 
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Standard Partial Outlier Outlier Unknown Control
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I)  ULOQ(3461.704) 
 LLOQ(0.666) 
Standard Partial Outlier Outlier Unknown Control
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8A2: STANDARD CURVES FOR SOME OF THE IMMUNOGLOBULINS ANALYSED 
 
 
Regression Type: Logistic - 4PL 
Std. Curve: FI = 44.0269 + (38578.1 - 44.0269) / (1 + (Conc / 8.77742)^-1.06633) 






Regression Type: Logistic - 4PL 
Std. Curve: FI = 71.7082 + (29356.2 - 71.7082) / (1 + (Conc / 139.011)^-1.14179) 




























I)  ULOQ(14.039) 
 LLOQ(0.013) 
Standard Partial Outlier Outlier Unknown Control
IgM (56)



























Standard Partial Outlier Outlier Unknown Control
 132 
 









8A5: BIOMEDICAL RESEARCH ETHICS COMMITTEE INITIAL APPROVAL 
 135 
 






















8A9: PROOF OF SUBMISSION FOR MANUSCRIPT 3 
 
 
